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CHAPTER 1 
GENERAL INTRODUCTION 
CHAPTER 1 
1 Viral hepatitis 
A majority of clinical hepatitis in man is caused by infection with hepatitis viruses. This 
is a group of hepatotrophic viruses differing in origin and structure (Table I). The clinical 
outcome of a viral hepatitis infection is comparable, starting with fatiqueness, anorexia, 
gastro-intestinal complaints, jaundice and liver enlargement. The serological markers, 
pathogenicity and severity of infection however are completely different. The characteri­
zed hepatitis viruses are: 
1. Hepatitis A virus (HAV) 
HAV is a picorna virus, which accounts for 20-25% of clinical hepatitis. HAV has a 
short incubation period of 2-7 weeks and is spread through the faecal-oral pathway. The 
host range of HAV is restricted to humans and some non-human primates. Infection with 
HAV results in a self-limited acute disease without chronicity (40). 
2. Hepatitis В virus (HBV) 
HBV has an incubation period of 28-160 days and is transmitted parentally. In high en­
demic regions maternal transmission is also of importance. The host range of HBV is 
restricted to humans and some non-human primates like chimpanzee and gibbon (160). In­
fection with HBV may result in a different clinical outcome, varying from a subclinical 
state to acute and chronic disease (5-10%). Patients with a chronic HBV infection are a 
high riskgroup for developing hepatocellular carcinoma (HCC)(112, 135). In 1% of the 
HBV infections an acute infection may become fulminant with a mortality rate of 80% 
(section 1.1). 
3. Hepatitis С vims (HCV) 
HCV was first classified as hepatitis non-Α non-B virus. Its incubation time and routes of 
transmission are the same as for HBV. The host range of HCV is also restricted to 
humans and some non-human primates. (40, 66). Fifty percent of the HCV infections will 
result in chronicity, with an increased risk to develop HCC (40). 
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4. Hepatitis delta virus (H5V) 
HÔV is a RNA virus, with a coat of HBV surface antigen (HBsAg). Ηδν is a defective 
virus, which needs HBV for succesfull infection. The routes of transmission are therefore 
related to that of HBV (50, 129, 130). Infection with H5V only occurs as a coinfection 
with HBV or as superinfection of a HBV carrier, both resulting in a different clinical 
outcome (section 1.2). 
Table I. Characteristic aspects of the identified hepatitis viruses in man 
Virus 
Genome 
Genome length 
Size 
Chronicity 
Incubation time (days) 
HAV 
RNA 
7.5kb 
27nm 
no 
15-49 
HBV 
DNA 
3.2kb 
42nm 
yes 
28-160 
HCV 
RNA 
lOkb 
34-37nm 
yes 
15-160 
HÍV 
RNA 
1.7kb 
35-37nm 
yes 
28-140 
HEV 
RNA 
7.5kb 
27-34ШП 
no 
15-63 
5. Hepatitis E virus (HEV) 
HEV was formerly classified as the epidemiological form of non-Α non-B hepatitis. It has 
a short incubation time of 2-9 weeks and transmission occurs via the faecal-oral route. 
Besides humans also some non-human primates like chimpanzee and rhesus monkey are 
susceptible hosts (40, 84). The clinical outcome of a HEV infection is comparable with 
that of HAV. In pregnant women, however, HEV has a relatively high mortality rate of 
20% (40, 83). 
As mentioned before, the viruses indicated in table I are the characterized hepatitis 
viruses. Thanks to the development of screening techniques for HAV, HBV, HCV and 
HSV in blood, the incidence of post-transfusional hepatitis has been reduced to 2-3% of 
the bloodtransfusions (138). However, in some of the post-transfusion hepatitis no serum 
markers of known hepatitis viruses can be detected, indicating that probably an unidenti­
fied agent is involved (3). Identification and characterization of unknown hepatotropic 
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agents will therefore remain important in future. 
Because HBV and HDV are important for the study as desenbed in this thesis, these two 
viruses will be discussed in more detail. 
1.1 Hepatitis В virus 
Despite good vaccination programs, HBV is still a major world health problem. 
Worldwide there are more than 250 million HBV carriers and annually about 2.5 million 
people die in consequence of a HBV infection. HBV is distributed worldwide with a high 
prevalence in Africa and Asia, where more than 20% of the population is HBV carrier. In 
highly developed countries like North America and Western Europe only 0.1%-1% of the 
population is HBV carrier. Dmg-abusers, health care personnel and homosexuals are on 
high risk for an infection with HBV in these countries (40). 
An infection with HBV will result in a different range of clinical outcome. Mostly a self-
limiting acute hepatitis will develop, followed by clearance of the virus and full recovery 
of the patient. In 1% of the patients with an acute hepatitis, a fulminant hepatitis will 
develop. This is characterized by rapid progression of liver failure, resulting in a mortali­
ty rate of 80% (87). In 5-10% of HBV infected patients, virus will not be cleared and a 
HBV infection may result in a chronic persistent or chronic active hepatitis. Chronicity is 
defined by the presence of HBsAg in the serum of HBV infected patients longer than 6 
months. Sometimes no symptoms are found and these patients are referred as "healthy" 
carriers (87). Epidemiological studies have demonstrated that a chronic HBsAg carrier 
state for more than two years is strongly associated with the development of HCC (112, 
135). 
HBV belongs to a group of structurally and genetically related hepatotrophic DNA 
viruses, the so called hepadna viruses. Other members of this group are: ground squirrel 
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hepatitis virus (GSHV), tree squirrel hepatitis virus (TSHV), woodchuck hepatitis virus 
(WHV), Pekín duck hepatitis virus (DHBV) and heron hepatitis virus (HHV) (126, 127, 
131, 148, 159). Because HBV does not infect tissue cultures and the common used 
laboratory animals, these above mentioned viruses and there respective hosts have been 
used as a model for investigation of the biological properties, infection mechanism and 
replication of HBV (28, 29, 79, 86, 140). 
1.1.1 Hepatitis В particle 
In serum of HBV infected patients particles with a diameter of 42 nm and 22 nm can be 
detected. The 42 nm particles are the HBV virions, also called Dane particles (Figure 1). 
Figure I. Besides Dane panicles also non-infectious spherical and filamen­
tous particles can be found in sera of HBV infected patients. 
The HBV virion has an inner core of 27 nm, containing HBV DNA, hepatitis В core 
antigen (HBcAg) and HBV DNA polymerase. The HBV core is covered by host derived 
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phospholipids containing the hepatitis В surface protein (HBsAg), forming the envelope of 
the virus. The 22 nm particles do not have a core and represent the non-infectious 
particles (Figure 1). These spherical or filamentous particles with a diameter of 22 nm 
consist only of host derived phospholipids containing HBsAg and are always in 1000-fold 
excess compared to the Dane particles (33, 159). 
1.1.2 Genome of HBV 
The HBV genome is a 3.2 kilobases (kb) long, circular, partly double stranded DNA 
molecule. In figure 2 the genetic organization of the HBV genome is shown. The long or 
L(-) strand is linear and has a fixed length of 3.2 kb, with a nick at position 1820 . The 
short or S(+) strand has a variable length of 50%-75% of the L(-) strand. Despite the 
nick in the L(-) strand the circular form of the partly double stranded DNA is maintained 
by base-pairing of the 5' ends of both strands over a length of about 200 nucleotides 
between the 11 base-pair directed repeats (DR1 and DR2)(99,158). 
On the L(-) strand four open reading frames (ORF's) encoding the HBV related proteins 
have been identified called the C, P, X and S ORF. The ORF's overlap with each other. 
The P-ORF overlaps with all ORF's, which means that the HBV DNA genome is read 
1.5 time (106). 
1.1.3 HBV ORF's and their translation products 
The C-ORF (Figure 2, 1818-2450) has two in frame startcodons and encodes two 
proteins: the structural nucleocapsid hepatitis В core antigen (HBcAg) and the non­
structural, secreted, hepatitis В e antigen (HBeAg). 
The C-gene of the C-ORF encodes the 22 kilodalton (TO) HBcAg. This protein is the 
major component of the virus nucleocapsid. (73, 159). 
The C-gene and Pre-C region of the C-ORF encode a precore protein. This protein 
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Figure 2. Schematic organization of the HBV genome. The C-, P-, X- and S-ORF's with their 
corresponding transcripts are indicated (159). 
consists of the entire HBcAg with additional 19 amino acids (aa) at its amino terminus. 
This 19 aa region functions as a signal sequence and targets the protein to the endoplas-
matic reticulum (ER), where it may be cleaved of and a 22kD precore protein derivative 
is formed (113, 115, 116, 192). This protein is secreted through the ER and Golgi 
apparatus, where further proteolysis takes place at the arginine rich carboxy terminus. 
This results in the secretion of a heterogenous population of 17kD proteins called HBeAg. 
The presence of HBeAg in serum of infected patients is always associated with ongoing 
virus replication (73, 159). 
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The P-ORF spans more that 75% of the virus genome overlapping the other three ORF's. 
The P-gene codes for the 90kD virus DNA polymerase, with reverse transcriptase and 
RNAse H activity similar to that found in retroviruses (131, 149, 159). 
The X-ORF is a highly conserved region and encodes for the 17Ш hepatitis Β χ protein 
(HBxAg, 90). The precise role of this protein is not known so far. HBxAg deletion 
mutants are still able to replicate in vitro (9, 94), implicating that HBxAg does not take 
part in HBV replication. There are however indications that HBxAg is involved in 
oncogenesis by trans-activation of homologous and heterogenous cellular transcriptional 
nuclear factors (33, 76, 163, 164). 
Figure 3. Structure and translation products of the S-ORF. The circles indi­
cate the glycosylation sites on the HBsAg proteins. 
The S-ORF exists of 3 in frame regions, each encoding a hepatitis В surface protein: 
small, middle and large HBsAg (104, 159). 
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In figure 3 a schematic overview of the S-ORF coding for the HBsAg proteins is shown. 
The S-gene of the S-ORF encodes the small HBsAg. The S-gene and PreS2 region encode 
for middle HBsAg. The PreSl, PreS2 and S region of the S-ORF encode for large 
HBsAg. Small HBsAg occurs in a 24kD non-glycosylated and a 27kD glycosylated form. 
Middle HBsAg appears in two glycosylated forms with a molecular weight of respectively 
33kD and 36kD. The molecular weight of large HBsAg is, depending on its state of 
glycosylation, 39kD or 42kD. 
The HBsAg proteins form, together with host derived lipids, the HBV coat and the fila-
mentous or spherical non-infectious 22 nm particles (16, 159, 167). 
Each HBV envelope has about 300-400 small HBsAg molecules and 30-40 middle and 
large HBsAg molecules (11, 160). In figure 4 the arrangement of the HBsAg proteins in 
the HBV coat is drawn schematically. 
The small HBsAg consists of three hydrophobic domains transversing the lipid membrane 
twice. The PreS2 and PreSl sequences are hydrophobic and are both located at the 
outside of the particles (50, 118). At the amino terminus of the small HBsAg two signal 
sequences (I and II) are present, that target the protein to the ER and causes translocation 
of the upstream sequences. 
Because small HBsAg is the major component of the envelope of HBV it is also indicated 
as major HBsAg. This protein is considered to play an important role in the attachment of 
Dane particles to a specific HBsAg binding protein present on human liver cells (section 
1.1.7). Large HBsAg is probably important for the secretion of Dane particles (section 
1.1.6). 
1.1.4 HBV DNA replication 
After entering the host liver cell the virus is uncoated and the naked core particles are 
transported to the nucleus by a mechanism which is not known so far. In the nucleus the 
S(+) strand of the HBV DNA is completed and a covalently closed circular HBV DNA 
(cccDNA) molecule is formed (101, 104, 159). This cccDNA serves as template for the 
transcription of a 3.5 kb viral RNA pregenome and the messenger RNA's (mRNA's) for 
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Small HBsAg Middle HBsAg 
Large HBsAg 
Figure 4. Schematic organization of the three HBsAg proteins in the lipid bilayer of HBVparticles. 
The upper and lower part of each drawing represent respectively the out- and inside of 
the particles. I and lì are signal sequences (50). 
the viral related proteins. The pregenome is packaged, together with the viral DNA 
polymerase, by the HBcAg to form immature core particles. Immediately after the 
formation of these particles, RNA-directed DNA synthesis commences, using the reverse 
transcriptase property of the viral DNA polymerase and the pregenome as template. The 
RNA-directed DNA synthesis is initiated by the binding of the DNA-polymerase to the 
pregenome at a specific primer protein binding site, epsilon (e), located at the 5' end of 
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the pregenome. After polymerisation of the first four nucleotides, the polymerase-
nucleotide complex is dissociated from the RNA template and translocated to the DR1 
repeat at the 3'end of the pregenomic RNA, where the DNA synthesis continues (Figure 
2, 172, 173). Besides reverse transcriptase activity the viral DNA-polymerase also 
possesses RNAse H activity. During the L(-) strand elongation the pregenome will be 
degraded by this RNAse H activity. The RNA degradation stops at the 5' DR1 repeat of 
the pregenome, leaving a part of the pregenome unaffected. This RNA fragment is 
translocated to the DR2 repeat of the L(-) strand, where it serves as a primer for the 
S(+) strand synthesis (103, 139, 140, 175). 
1.1.5 HBV transcription 
Transcription of the HBV genome is a very complicated process in which several 
regulatory elements play a role. As indicated in table II, the four ORF's on the L(-) 
strand of the HBV genome are transcribed by the host cellular transcriptional machinery 
to produce RNA transcripts of approximately 3.5kb, 2.4kb, 2.1kb, and 0.7kb. (126, 157). 
The 3.5kb transcript has a double function. It serves as template for the RNA-directed 
DNA synthesis (section 1.1.3) and as mRNA for the DNA polymerase, the HBcAg and 
HBeAg. The 2.4kb transcript is the mRNA for large HBsAg, the 2.1kb transcript the 
mRNA for small and middle HBsAg and the 0.7kb RNA molecule is the mRNA for 
HBxAg. 
The level of transcription of the HBV genome is regulated by specific promotors and 
enhancers. On the HBV genome four promotors have been identified: The C-ORF 
promotor for the 3.5kb transcript, the S-ORF promotor for the 2.4kb transcript (Spi), the 
S-ORF promotor of the 2.1kb RNA transcript (SpII) and the X-ORF promotor (104, 126, 
159, 191). Several regulatory elements play a role in the activity of these promotors. 
These regulatory elements are host cell derived, but on the HBV genome also two so 
called enhancers (Eni and Enll) have been identified, which are capable to activate 
transcription of HBV genes but also heterologous genes, independent of orientation and 
position (158, 180, 191). 
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Table II. HBV transcripts, transcription regulatory elements and translation products. 
Transcript 
Promotor 
Position promotor on 
the HBV genome 
Translation products 
Regulatory elements 
3.5kb 
С 
1701-1785 
Pregenome 
DNA-
polymerase 
HBc/eAg 
Eni 
2.4kb 
Spi 
2884-2870 
Large HBsAg 
Eni, ΕηΠ, 
HNF-1 
2.1kb 
SpII 
3156-3174 
Small HBsAg 
Middle HBsAg 
Eni 
0.7kb 
X 
1239-1276 
HBxAg 
Eni 
Eni located on position 966-1308 of the HBV genome, regulates the activity of C-, S, and 
X-ORF promotors. EnII is situated at position 1645-1804 of the HBV genome and 
regulates the activity of the S-ORF promotors Spi and SpII (17, 70, 150, 191). Both 
enhancers contain binding sites for multiple cellular transcriptional factors (30, 145, 158), 
but HBxAg also plays a role as activator of the HBV enhancers (139). 
The replication of HBV is cell type specific and several regulatory factors in the HBV 
genome replication have been identified which may account for the liver specific 
replication of HBV: 
- The Spi promotor shows a strong preference for well differentiated hepatoma cell lines 
(18, 44, 100). Moreover, liver specific human nuclear transcriptional factor (HNF1) 
enhances the Spi promotor activity (126). 
- The SpII promotor shows a moderate preference for well differentiated hepatoma cell 
lines (18, 44). 
- Enll activity is restricted to highly differentiated hepatoma cell lines (158, 180, 189). 
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- On position 356-366 of the HBV genome an other regulatory sequence has been identi 
fied, which increases the enhancer regulated transcription. The nucleotide sequence of 
this regulatory element shows homology with glucocorticoid receptor binding sites and 
is called the glucocorticoid responsive element. It induces HBV gene expression in well 
differentiated hepatoma cell lines (59), by augmenting the functions of the HBV 
enhancers (35, 160, 161, 162). 
1.1.6 Dane particle formation 
Formation of Dane particles is essential for fundamental functions of HBV virions: the 
delivering of the HBV genome to susceptible host cells, for viral replication, protection 
the HBV genome from degradation and secretion of virions from infected cells. 
The assembly of Dane particles is a complex, still unclear process and is characterized by 
following events: 
- Packaging of the pregenome and DNA-polymerase by HBcAg into immature core 
particles (section 1.1.3). 
For (he formation of replicative competent nucleocapsids the correct packaging of the 
pregenome is essential. On the 5' end of the pregenome an encapsidation signal has been 
identified, which is preferential recognized by the viral DNA-polymerase (5, 29, 28, 61, 
64, 65). After recognition of the pregenome by DNA-polymerase the RNA/protein 
complex will be encapsidated by HBcAg. At the carboxy-terminus of the HBcAg four 
stretches of arginine rich-residues have been identified, as found in other RNA/DNA 
binding proteins (47, 61). These sequences are essential for an effective RNA encapsidati-
on (61). 
HBcAg is only present in dimers in the nucleocapsid. Dimerization of HBcAg takes place 
via four cysteine-residues on the carboxy-terminus of HBcAg. Although the presence of 
these cysteine residues is not essential for the formation of core particles, they are 
important for the stabilization of the nucleocapsids and may therefore be of biological 
significance in protecting the core particle against its cellular environment (108, 109, 192, 
193). 
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- Encapsidation of the immature nucleocapsids, presumably by interaction with HBsAg 
at the ER membrane, followed by budding into the lumen of ER to form mature Dane 
particles (111, 112, 117, 165). 
The small, middle and large HBsAg play different roles in the packaging of nucleocap-
sids. Packaging of core particles by small HBsAg only occurs when large HBsAg is 
present (184, 188). Presence of middle HBsAg is not necessary for Dane particle 
formation. Based on these facts and because overexpression of large HBsAg inhibits 
secretion of non-infectious particles (31, 114, 188), it has been suggested that large 
HBsAg might be the regulator of nucleocapsid release. By retaining the HBsAg proteins, 
it might concentrate the HBsAg proteins at certain places in the ER membrane, generating 
sites of viral budding (16, 165, 188). 
Secretion of immature nucleocapsids can only occur in the presence of HBsAg, impli-
cating that in HBV budding HBsAg proteins must interact with the core proteins (16). 
1.1.6 Pathogenesis of HBV infection 
Normal histology in livers of asymptomatic HBsAg carriers (74), cell lines stably 
transfected with HBV DNA (1, 3, 140, 150, 184) and HBV transgenic mice (29, 107, 
141) producing complete HBV particles and viral antigens, suggest that HBV is not 
directly cytopathic (59). Viral induced hepatitis is correlated with mononuclear infiltrati-
ons and hepatocellular necrosis. Because liver cell necrosis and inflammatoiry infiltrates 
are closely related, the host immune repsonse seems to be responsible for the liver cell 
injury during HBV infection (105). 
A schematic overview of the immune mediated liver cell injury is shown in figure 5. 
HBcAg and histocompatibility class I antigen (HLA I), both present on the surface of 
infected hepatocytes, are recognized by specific cytotoxic T-cells (71, 76, 107). The T-
cells subsequently induce lysis of the infected hepatocytes, allowing intracellular virus to 
enter the circulation. Humoral antibodies will neutralize the released viruses and prevent 
reinfection (4, 37, 122, 123). 
14 
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Figure 5. Schematic overview of immune mediated liver cell injury in HBV 
Infection (45). 
Further evidence favouring the theory of immune mediated liver cell injury during HBV 
infection are: 
- Reactivation of virus infection during immunosuppression. Termination of 
immunosuppressive therapy results in restoration of cellular immunity and in massive 
hepato-cellular necrosis (4). 
- High prevalence of HBV carriers among children of HBeAg positive carrier mothers. 
Maternal HBeAg can transverse the placenta and will induce immunological tolerance in 
neonates for both HBeAg and HBeAg. Infected hepatocytes are not destroyed, which 
implicates that viruses will not be cleared, resulting in a chronic carrier state (68). 
In mice transgenic for large HBsAg and unable to secrete large HBsAg from hepatocytes, 
HBsAg-aggregates accumulate in the ER of these cells. High concentrations of HBsAg 
have proven to be directly cytotoxic (32, 105), but in human liver such high levels of 
intracellular HBsAg are only demonstrable in, scarcely present, so called "ground glass 
cells". Gilles et al. (52) suggested however, that intracellular HBsAg is able to alter the 
15 
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hepatocyte physiology in a manner, by which it becomes sensitive for injury by interfe-
ron-T. It is therefore possible that local production of interferon-τ by T-cells may also 
contribute to viral clearance and liver cell injury during HBV infection (52). 
1.1.7 HBV species tropism 
The host range of HBV is restricted to humans and some non-human primates like 
chimpanzee and gibbon (159). The species tropism of HBV may be a consequence of: 
- the specific interaction of the viral envelope proteins with a component of the plasma 
membrane of human liver cells, which enables HBV to enter these cells. 
- the need of tissue specific factors for the activity of viral promotors and enhancers 
(section 1.1.4, 89). 
HBsAg proteins may play an important role in the recognition of a specific receptor 
molecule on the surface of human liver cells. In literature it has often been mentioned, 
that the PreSl sequences of large HBsAg exhibit a binding site for human liver plasma 
membrane proteins (28, 43, 119, 122), but until now no PreSl receptor on the human 
liver cells has been isolated. However, it has been demonstrated that small HBsAg binds 
specifically to intact human hepatocytes (88). 
Recently, endonexin II, a 34kD plasma membrane protein present in human liver was 
identified as a specific small HBsAg binding protein (62). Human liver endonexin II 
belongs to the annexin family, a group of highly related proteins that all bind to phospho­
lipids, a process which is Ca2+-dependent (8, 41, 75, 77). The annexins all have the same 
primary structure: a small amino terminal domain and a core domain that consists of a 
four- or eightfold repeat of a 70 aa (Figure 6), with a highly conserved sequence. This 
core domain is responsible for the calcium- and phospholipid binding capacity of the 
annexins. The heterologous amino terminus of these proteins might confer the different 
functions of the annexins (39, 40). 
The precise role of the annexins is not yet known, although involvement in exo- and 
endocytosis, organization of lipid metabolism, forming of calcium channels and inter­
action with cytoskeletal elements are mentioned (56, 92, 132, 134). For endonexin II 
16 
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Figure 6. The primary structure of six members of the Annexin family (41). 
the formation of calcium channels has also been described in vitro (132). This implicates 
that endonexin II must have a transmembrane localization, but in human endonexin II no 
transmembrane signals have been demonstrated so far (36, 75, 155). Recently the 
structure of human and chicken endonexin II have been identified (6, 71). Human 
endonexin II exist of four domains, each containing five helixes. The centre of endonexin 
II is a pore which is lined by the four domains, containing hydrophilic residues. This 
structure is more often seen in integral membrane proteins than in water-soluble proteins. 
The structure of endonexin II also has several features in common with ion-channel-
forming proteins (6, 71). 
Recently an additional role of endonexin II as HBsAg binding protein and probably as 
HBV receptor was mentioned (62). Spontaneously derived anti-idiotypic antibodies 
reacting with HBsAg, after immunization of rabbits with purified native human liver 
endonexin II, confirmed the relationship between human liver endonexin II and HBsAg 
(63). Demonstration that human liver endonexin II is involved in HBV infection is 
however still in progress (this thesis). 
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Although HBV is a hepatotrophic virus, HBV DNA, transcripts and antigens have also 
been demonstrated in extrahepatic tissues like kidney, skin, pancreas, lymphoid tissues, 
placenta, gonads, thyroid, and adrenal glands (7, 10, 79, 102, 103, 185, 187, 190). The 
extra-hepatic localization of HBV DNA reveals that the hepatocyte is not the only cell 
type susceptible for HBV infection. Probably the cell types in which HBV DNA is found, 
all bear a receptor protein for HBV, but only the intracellular environment of the 
hepatocyte is favourable for HBV replication. This suggests, that if human endonexin Π is 
the HBV receptor, it should be expressed in different tissues. 
1.2 Hepatitis delta virus (Ш ) 
Hepatitis delta virus (H5V) was first described in 1977 by Rizzetto and coworkers as a 
novel nuclear antigen in liver biopsies of patients chronically infected with HBV (129, 
130). H5V is a defective virus. For its transmission it is dependent on the presence of 
HBV: It needs HBsAg delivered by HBV to complete its own infection cycle. Infection 
Figure 7. The components of the H6V panicle. 
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can therefore only occur as coinfection with HBV or as superinfection of HBV carriers. 
In case of coinfection, HSV production depends on the virulence of the underlying HBV 
infection. The clinical symptoms may vary from mild to fulminant illness, mostly with 
full recovery and only 1-2% chronicity (51, 130). When superinfection of an HBV carrier 
occurs, a chronic HSV infection will develop in most of the infections. Occasionaly, HSV 
superinfection may result in seroconversion to a HBsAg negative state, implicating the 
clearance of HSV, but generally HSV superinfection will aggravate symptoms caused by 
HBV infection. Asymptomatic chronic HBsAg carriers may develop hepatitis after 
superinfection with HSV and the course of an active hepatitis may be accelerated, resul­
ting in a higher mortality rate (13, 51, 116, 130). Chronic HBsAg carriers superinfected 
with HSV are at higher risk of developing HCC compared to HBsAg carriers infected 
with HBV only (165). 
The distribution of HSV is worldwide with high prevalence in South America, the Middle 
East, Western Africa, Southern Europe and some islands in the South Pacific. In 
Northern Europe, North America and Australia Ш is only present in high risk groups 
like drug-abusers (51, 60, 110). 
1.2.1 HSV particle 
As indicated in figure 7, HSV is a 36 nm enveloped particle with a core containing the 
HÔV specific delta antigen (HSAg) and the HSV RNA molecule (78, 80, 87, 99, 168). 
The coat of HSV consists of HBsAg provided by HBV with the same polypeptide 
composition as the 22 nm HBsAg particles: predominantly small HBsAg, 5-10% middle 
HBsAg and virtually no large HBsAg (11). Besides humans and chimpanzees, wood-
chucks and Pekin ducks are also susceptible hosts of the HSV. In the latter two cases the 
coat of HSV is provided by the HBV related WHV and DHBV respectively (34, 58, 81, 
86, 124-126, 150, 152, 156). 
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1.2.2 Genome of H6V and its replication 
It has been estimated by electronmicroscopy and gel-electrophoresis, that H5V RNA is a 
circular, single stranded molecule with a length of approximately 1.7kb. Electron-
microscopy showed a rodlike structure, which was confirmed by sequence analysis. Sixty-
one percent of the RNA nucleotides are present in base pairs, forming a rodlike structure 
and a further 6% takes part in G-U matches. 
In hepatocytes of infected patients not only the genomic RNA but also the complementa­
ry, antigenomic RNA can be detected. Northern blotting analysis established that in 
virions only the genomic form is packaged (77, 79, 165, 166). 
In HSV infected livers DNA replication-intermediates have never been demonstrated. 
Mono- and multimene length RNA molecules, however, were detectable on Northern blot 
(25, 26, 80). Therefore a rolling circle mechanism for Ш RNA replication, as has been 
reported for some virusoids (14), has been postulated (25). In figure 8 the rolling circle 
mechanism is shown schematically. First the genomic Ш RNA is copied by the host 
delivered RNA-polymerase (step 1) resulting in the production of multimene antigenomic 
RNA. The antigenomic strands are cleaved at specific sites (step 2) generating monomeric 
antigenomic strands, which are subsequently circularized (step 3). The antigenomic 
circular strands serve as template for the production of multimene genomic strands (step 
4), which are cleaved and circularized (step 5 and 6) to form circular HÔV RNA again. 
For completion of the H5V replication cycle, it is essential that multimene RNA is 
cleaved in unit-length Ш RNA and subsequently ligated to form the circular RNA 
genome. Both HSV genomic and antigenomic RNA are able to cleave and ligate auto­
nomously in the presence of Mg2 + ions. This was proven by the following experiments: 
After removal of Mg2 + from the incubation medium by the addition of EDTA, spon­
taneous religation of the cleaved RNA was reported. Religation only occurs when the 
concentration of EDTA exceeds that of Mg2* and the direction of this reversible reaction 
is therefore determined by Mg2+-ion concentration (143, 144, 176, 178). 
Apart from Mg2+-ion concentration, the secondary structure surrounding the specific 
20 
GENERAL INTRODUCTION 
Figure δ. Rolling circle mechanism of the HSV RNA replication (82). 
autocleavage sites and indirectly the length of the RNA molecule are important for 
autocleavage (176, 178). The minimal sequence, needed for this process was determined 
using in vitro synthesized H6V RNA from plasmids containing HôV cDNA with variable 
genome length. The genomic RNA fragment still undergoing autocleavage was 133 
nucleotides long and situated between nucleotide 654-786. For the antigenomic RNA the 
minimal sequence needed was 118 nucleotides and situated between nucleotide 818-936. 
Plasmids containing HÔV cDNA of variable lengths showed that the autocleavage site for 
the genomic RNA is situated on position 685-686 and for the antigenomic RNA on 
position 901-900 (15, 89, 176, 178). Although in vitro cleavage and ligation of the H5V 
RNA is observed, the biological relevance of this observation still has to be determined. 
On Ηδν RNA 5 putative ORF's have been described, of which only one has shown to be 
functionally active (99, 174). This ORF is located on the antigenomic RNA strand and 
encodes the only known HSV related protein: the hepatitis delta antigen (H<5Ag). In 
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Figure 9. RNA molecules involved in HbV RNA replication. The genomic, anti-
genomic and the 800 nucleotide polyadenylated mRNA for the HbAg are indica­
ted. The circles represent the self-cleavage sites, the rectangles the polyadenylati-
on single, the squares the polyadenylation site and the open arrows the ORF of 
H6Ag (157). 
infected cells a cytoplasmic polyadenylated antigenomic mRNA is found, that functions as 
as mRNA for HÔAg. Site-directed mutagenesis showed that this RNA is essential for 
HÔAg synthesis (67, 68, 157). In figure 9 the schematic structure of the 3 HÔV RNA 
molecules are drawn. 
Comparison of animal and human derived cDNA sequences of Ш RNA from different 
isolates showed variation with a divergence of 11-17% only in restricted regions on the 
genome (21, 24, 71, 99, 138). The autocleavage sites, the polyadenylation signal (at 
position 952), the polyadenlylation site (at position 953), and the ORF of the H5Ag are 
highly conserved regions of the HôV genome (Figure 9). This implicates that these 
regions all provide essential functions (21, 72, 81, 99, 136, 182). 
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1.2.3 Hepatitis delta antigen 
In sera and livers of infected patients, two H5Ag specific proteins with a molecular 
weight of respectively 24kD (SôAg) and 27kD (LMg) are detected. These two proteins 
are identical in sequence, except that the LMg contains an additional 19 amino acids at 
its C-terminus (49, 134). During the RNA-directed RNA synthesis the action of the host 
encoded enzyme RNA duplex unwindase, which causes RNA unwinding by exserting 
covalent nucleotide changes, is probably involved in nucleic acid substitution at the 
stopcodon of the SÔAg (167), resulting in the loss of this codon. During RNA replication 
the stopcodon of the 24kD H5Ag ORF is readthrough and a mRNA, encoding the large 
214aa instead of the small 195aa HÔAg, is transcribed (22, 95, 181). LMg is thus formed 
due to sequence microheterogeneity at the stopcodon of the 24kD small HSAg coding 
mRNA (21, 95). 
The fact that both forms of HôAg and mRNA coding for these proteins are found in 
nearly all H5V patients, suggests a functional significance for both proteins. 
The localization of the HôAg during an H5V infection was determined using immuno-his-
tochemical methods. The H5Ag is predominantly expressed in the nuclei of HÔV infected 
hepatocytes (26, 58). For H5Ag and HÔV RNA an extrahepatic localization, as can be 
seen for HBsAg and HBV DNA, has never been reported. 
1.2.3.1 HiAg in HSV RNA replication 
Transfection experiments of HSV RNA in HôAg producing and non-producing cell lines 
have established, that HSV genome replication is independent of HBV sequences or 
functions, but is dependent on the presence of HÔAg (53, 86, 96, 99). The two forms of 
H5Ag differ in their ability to promote H5V replication. Only SSAg is competent in this 
respect and LMg inhibits the action of S5Ag. A schematic reflection of the HSAgs with 
their functional domains is given in figure 10. On HSAg two domains have been iden-
tified, which play an important role in HSV RNA replication: 
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Figure 10. Schematic organization of S- and LMg with their functional do­
mains (20). 
The RNA binding domain: Incubation of cell lysates, containing HMg and in vitro 
synthesized HÔV RNA, demonstrated a specific interaction of HMg and HSV RNA (19, 
86). The precise localization of the HSAg-HSV RNA interaction site on the HôAg, was 
determined using recombinant H5Ag proteins of different sizes in an RNA mobility 
assay. HÔAg proteins containing the middle one third of the HSAg sequence were the 
only proteins forming a slow moving RNA-protein complex (23, 91). This region is 
highly hydrophobic and contains many basic amino acid residues, as found in other 
DNA/RNA binding proteins. Because the RNA binding domain is highly conserved in 
HSV RNA of different isolates, the HMg-HSV RNA interaction must be an important 
step in the HÔV life cycle. 
• Leucine zipper-like domain: On the HÔAg sequences closely resembling leucine zipper 
sequences are present, which enable proteins to form dimers or multimers. In vivo 
H6Ag occurs in oligomers and the leucine zipper sequences have shown to be essential 
for formation of these oligomers. As mentioned before does LMg inhibit the action of 
SÔAg. Recombinant LMg, where the amino terminal leucine zipper sequences were 
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deleted, showed no inhibitory effect (27). The presence of LMg in an oligomer 
probably disrupts the correct conformation of the complex and by this way prevents the 
RNA replication (171, 182). This was suggested because the presence of only 11% 
LMg of the total of HSAg is sufficient to inhibit the action of the SSAg for 88% (22). 
At the start of an HSV infection only SSAg is expressed. During time of infection the 
S/L HSAg ratio increases. Probably the two proteins regulate the HSV replication in a 
way, that it becomes self-limited. This self-limiting HSV RNA replication prevents acute 
HSV infection to become fulminant, which often results in the death of the patient (22, 
54, 179). 
Although it is obvious, that SSAg plays a key role in the HSV RNA replication, the 
precise function is still unknown. Probably it is important for the transport of the HSV 
RNA to the nucleus of the host cell, but it may also participate in more directly since it 
binds to the HSV RNA (183). 
1.2.4 Ш particle formation 
H6V, as mentioned, has a coat of HBsAg surrounding the ВД RNA and HSAg. 
Somehow during the HSV infection cycle, HSV particle formation must take place to form 
mature virus particles. Although little is known about this complex process, the role of 
the different forms of HSAg and HBsAg in this respect has been studied. Co-transfection 
experiments with plasmids expressing HBsAg and plasmids containing either the cDNA 
for SSAg or LMg have demonstrated, that SSAg alone is not sufficient for HSV particle 
formation. LSAg, however, can be packaged efficiently (20, 137). SSAg is only packaged 
when the LSAg is present. This finding suggests that a direct interaction between these 
two proteins is important for particle formation. Co-transfection experiments with a 
mutant LSAg, lacking the leucine zipper like sequences (Figure 10), confirmed this 
hypothesis. Using mutant LSAg no SSAg was co-packaged into virions, indicating that 
protein interactions via the leucine zipper motifs are involved in HSV assembly (27) and 
that LSAg plays a crucial role in this process. 
HSV particles were only detected in in vitro culture systems, when HBsAg was available. 
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HBsAg is therefore essential for completion of HSV particle maturation. It is interesting 
that the presence of small HBsAg was already sufficient for the formation of HSV like 
particles (137, 154, 170). 
1.2.5 Cytopathy of Ш 
It is generally accepted that liver damage caused by HBV infection, is mainly the result of 
the host immune response of cytotoxic T-cells to HBcAg present on hepatocytes (section 
1.1.6). The expression of HSAg and HSV RNA however is always associated with hepatic 
failure (39, 129, 130, 145, 147). Several mechanisms for HSV related cytotoxicity have 
been postulated: 
- For SSAg a direct cytotoxic effect on host cells has been demonstrated in transfection 
experiments using cDNA encoding SSAg (97). 
- Competition for host cell enzymes needed for RNA replication has been mentioned (48). 
- For the antigenomic HSV RNA two stretches of respectively 48 and 44 nucleotides were 
identified, that are complementary to human 7SL RNA of the signal recognition protein 
(SRP, 110). SRP is important for the translation of secretory and membrane bound 
proteins. Base-pairing of the antigenomic RNA with or cleavage of this 7SL RNA, due 
to ribozyme activity of HSV RNA, would prevent the formation of the SRP. The 
infected host cell would therefore be depleted of the SRP and the production of 
secretory or membrane bound proteins may be delayed. (13, 185). 
1.2.6 Influence of HSAg on HBV RNA expression 
In co-transfection experiments with HBV DNA and HSV cDNA the levels of HBV RNA 
were decreased in comparison to transfection with HBV DNA alone. When cotransfec-
tions were performed with cDNA encoding for HSAg, a suppression was also observed, 
suggesting that HSAg is responsible for this phenomenon (38, 97, 177). The mechanism 
of this inhibitory process on HBV replication and production of Dane particles is still 
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unknown, but it may explain how in some HBV carriers superinfected with H6V the HBV 
positive state of the patient is lost (84). 
1.3 Background and aim of the study 
HBV displays a strong host and tissue tropism: It only infects humans and some non-
human primates and predominantly replicates in the liver of these species. This species 
and tissue tropism suggest that a specific receptor on the liver of the susceptible host 
might exist. Recently the 34ГО human liver protein endonexin II was identified as a 
specific small HBsAg binding protein (62). After immunization of rabbits with endonexin 
II purified from human liver tissue, not only antibodies against this protein, but also anti-
idiotypic antibodies reacting with HBsAg, were generated. These results indicate, that the 
idiotypic antibody mimics a region of the endonexin II, which binds to HBsAg. Although 
these results strongly suggests, that a receptor-ligand relationship between these proteins 
might exist, a role of human liver endonexin II as HBV receptor still has to be confirmed. 
The aim of the study described in this thesis was, therefore, to further establish the 
involvement of human liver endonexin II in the initial steps of HBV infection and in the 
species and tissue tropism of HBV. 
Because the envelope of Ηδν is constituted of HBsAg, provided by HBV, these viruses 
might use the same receptor for attachment to human liver cells as initial step in their 
infection cycle. We were therefore interested if H5V might also be able to interact with 
human liver endonexin II. 
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CHAPTER 2 
Summary 
In a previous study we identified human liver endonexin Π (ΕΠ) present on human 
hepatocyte plasma membrane, as a specific hepatitis В surface antigen (HBsAg) binding 
protein. Recently we also showed the spontaneous development of anti-idiotypic (anti-
HBsAg) antibodies in rabbits immunized with Ell and in chicken immunized with F(ab)'2 
fragment of rabbit anti-EII IgG. These findings suggest the existence of a receptor-ligand 
relationship between Ell and HBsAg. In the present study, we demonstrate that small 
HBsAg conjugated to 10 nm colloidal gold also binds specifically to human hepatocytes. 
Invagination of the coated pit region at the HBsAg binding sites on the human hepatocyte 
plasma membrane results in the internalization of the HBsAg-gold particles. The binding 
and consequently the internalization of HBsAg is inhibited by anti-EII antibodies or anti-
idiotypic (anti-HBsAg) antibodies. These findings indicate that EH is directly involved in 
the binding and uptake of hepatitis В envelope proteins and underline the assumption that 
Ell is the hepatitis В vims receptor. 
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Introduction 
Although considerable information on the molecular biology of hepatitis В virus (HBV) 
has been gained in the last decades, still little is known about the mechanism of attach­
ment and penetration of HBV into human hepatocytes, the natural host cells of HBV. 
Binding of viral particles to plasma membranes of human hepatocytes is considered as an 
important initial step in viral entry and infection of HBV. The envelope of HBV is 
composed of three polypeptides: the small, middle and large hepatitis В surface antigen 
(HBsAg) (13). These three proteins might play an important role in recognizing specific 
molecules on the surface of the human hepatocytes. The three HBsAg proteins have the S 
sequence in common, but differ in their amino terminal extension. Middle HBsAg 
consists of the S and PreS2 sequences, while the large HBsAg consists of the S, PreS2 
and PreSl sequences. PreSl sequences have frequently been suggested as the binding site 
of the HBV on hepatocytes (1, 9, 10), but (a) human liver protein(s) that specifically 
bind(s) to PreSl peptide has not been identified so far. Recently we have identified 
endonexin II (Ell), isolated from human liver tissue, as a specific HBsAg binding protein 
(3). Furthermore, we described the spontaneous development of anti-idiotypic (anti-
HBsAg) antibodies in rabbits immunized with human liver Ell and in chicken immunized 
with F(ab)'2 fragment of rabbit anti-EII IgG (4). These antibodies are able to compete 
with Ell for the binding to HBsAg, indicating that the anti-idiotypic antibodies mimic a 
the region of the EH, that interacts with HBsAg. These findings strongly suggest the 
existence of a receptor-ligand relationship between HBsAg and ЕП. 
In the present study, we report evidence at the ultrastructural level for the specific 
binding and internalization of small HBsAg by human hepatocytes. The binding and 
internalization of small HBsAg are inhibited by anti-EII or anti-idiotypic (anti-HBsAg) 
IgG's. 
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Materials and methods 
Hepatocyte isolation 
Human livers were obtained from organ donors with permission of the local commitee on 
human experimentations and informed consent of the family. The hepatocytes were 
isolated by a two-step collagenase perfusion according to the method of Rijntjes et al. 
(1986). Collagenase was obtained from Boehringer (Mannheim, Germany). Viability of 
the cells, as determined by trypan blue exclusion, was 90%. The cells were seeded at a 
density of 2x10s cells /cm2 in Williams E medium (WEM) supplemented with 10% fetal 
calf serum (FCS), 2mM L-glutamine, 50nm dexamethasone, 0.02U/ml insulin, 2,5/ig/ml 
fungizone, 100/zg/ml vancomycin, 50/ig/ml gentamycin. Cells were cultured for 3 days 
prior to use for ultrastructural experiments in 6 well dishes (Costar) coated with extracel­
lular matrix obtained from human liver tissue (11). Cells that were not used directly for 
experiments were cryopreserved as described previously (11). 
Radio-labelling of HBsAg 
Recombinant yeast derived small HBsAg was kindly provided by Dr. Miller (Merck 
Sharp & Dohme, Research Laboratories Westpoint, PA, USA,(2)). Two micrograms of 
HBsAg were labelled with Na125I (Amersham, Buckinghamshire, England) using Iodogen 
(l,3,6,4-tetrachloro-3a,6a diphenyl glycouril (Pierce, Rockford, IL, USA) as described 
previously (6). Specific activity was 107 counts per minute (cpm)^g. 
The antibodies 
Anti-endonexin II (anti-EII) antibodies were obtained from rabbits immunized with 20 μg 
recombinant human liver Ell in complete freunds adjuvant as described previously (4). 
Antibodies were initially purified by protein A-sepharose (Pharmacia, Uppsala, Sweden) 
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column chromatography and subsequently applied to an affinity column, prepared by the 
coupling of purified recombinant yeast human liver Ell to CNBr-activated Sepharose 
(Pharmacia) as described (4). Fab'2 fragments were prepared from purified rabbit anti-
endonexin II IgG's by digestion with pepsine for 16 hrs at 37°C. After digestion the 
preparation was purified by protein A column chromatography and the Fab'2 fragment 
was used for immunization of chickens for production of anti-idiotypic (anti-HBsAg) 
antibodies. Anti-HBsAg IgG's were applied to an affinity column, prepared by the 
coupling of recombinant small HBsAg to CNBr-activated Sepharose (Pharmacia) as 
described (4). Non-immune serum (NIS) IgG's were isolated as described (Hertogs et al. 
1994) and used in control experiments. 
Binding of radio-labelled small HBsAg to human hepatocytes 
Cryopreserved hepatocytes were thawed as described (6) and resuspended in WEM 
containing 0.5% bovine serum albumin (BSA). 100.000 cells were incubated for Ihr at 
4°C to reduce non-specific binding. This was followed by a 1 hr incubation with rabbit 
anti-EII, chicken anti-HBsAg and non-immune serum (NIS) IgG's, diluted 1:10 in 
WEM/0.5% BSA. 100 ng radio-labelled HBsAg was added and cells were incubated for 
additional 2hrs in presence of the antibodies. Cells were subsequently washed 3 times 
with WEM and bound HBsAg was determined in a gamma-counter. Non-specific binding 
was determined by incubation with radio-labelled ligand in presence of 20-fold excess of 
unlabelled HBsAg. All experiments were performed in duplicate. 
Labelling of HBsAg with 10 nm colloidal gold 
HBsAg was coupled to colloidal gold and used as a tracer for binding studies and uptake 
of HBsAg by human hepatocytes. The preparation of the 10 nm gold-solution and the 
coupling of the gold to the HBsAg were performed according to the method as described 
by Slot & Geuze (1985). The gold particles were coupled to 200 μg HBsAg at pH 7.8. 
Gold conjugated HBsAg was separated from free HBsAg and unbound gold particles by 
centrifugation on a 10% glycerol cushion in phosphate buffered saline (PBS) with 0.1% 
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BSA for Ihr at 25.000 g and 4 eC. The HBsAg-gold pellet was resuspended in PBS and 
used directly for binding and internalization studies. 
Binding and internalization of HBsAg-gold by human hepatocytes. 
After 3 days of culture, human hepatocytes were incubated for 1 hr at 4 e C in WEM 
containing 1% BSA and subsequently for 1 hr with rabbit anti-EII (50/tg/ml) or NIS 
IgG's (140μg/ml) diluted in 1:10 in WEM/1% BSA. The HBsAg-gold pellet was diluted 
1:10 in WEM/1% BSA and added to the cells. After 2 hrs of incubation at 4 eC in the 
presence of the antibodies, hepatocytes were washed three times with ice-cold WEM and 
kept respectively for 0, 5, 10 and 30 minutes at 37°C. The cells were washed 3 times 
with ice-cold PBS and fixated for 0.5 hr with 2% glutaraldehyde in PBS at 4°C. 
To investigate whether chicken anti-idiotypic (anti-HBsAg) IgG's were able to block the 
binding and uptake of HBsAg-gold particles by human hepatocytes, following experiment 
was performed: HBsAg was preincubated for 0.5 hr with 1:100 dilution of chicken anti-
HBsAg (80/ig/ml) or NIS (140μg/ml) IgG's at room temperature, before HBsAg-gold was 
added to the cell cultures. 
Standard electron-microscopy 
The fixed hepatocytes were harvested, resuspended in 2% agarose at 60°C and pelleted. 
The cell pellet was cut into 1 mm3 pieces and postfixed with 1 % osmium tetra-oxide for 
20 minutes at 4°C. The cell blocks were dehydrated with ethanol and embedded in epon. 
Ultrathin sections were counterstained with uranyl acetate and lead citrate and were 
examined with a Philips EM 301 at 80 kV. 
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Results 
Binding of radio-labelled small HBsAg to human hepatocytes 
In previous experiments we demonstrated that small HBsAg is able to bind specifically to 
intact human hepatocytes in a saturable manner but not to rat hepatocytes (Leenders et al. 
1990). EH was identified as a highly specific HBsAg binding protein and excess Ell in 
binding experiments is able to inhibit the binding of small HBsAg to human hepatocytes 
(Hertogs et al. 1993). To investigate whether anti-EII or anti-idiotypic (anti-HBsAg) 
antibodies were also able to inhibit the binding of radio-labelled small HBsAg to human 
hepatocytes. Binding studies were performed in the presence of rabbit anti-EII, chicken 
Figure 1. Specific binding of radio-labelled small HBsAg lo intact human 
hepatocytes in the presence of 10% non-immune serum, rabbit anti-
EII, chicken anti-idiotypic anti-HBsAg antibodies. 
anti-idiotypic (anti-HBsAg) or NIS IgG's. As shown in figure 1, binding of small HBsAg 
to human hepatocytes was specifically inhibited by both anti-EII and anti-HBsAg 
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antibodies as compared to the incubations with NIS IgG's. Incubation with 1:10 dilution 
of the antibodies did not completely inhibit the binding of HBsAg to the hepatocytes. 
However, when a 1:5 dilution of the rabbit anti-EII IgG preparation (50/ig/ml) was used 
in the incubation, specific binding of HBsAg was totally abolished (result not shown). 
Chicken and rabbit NIS IgG's had similar effects in the binding studies. The results were 
referred to experiments using rabbit NIS IgG's. 
Binding of HBsAg-gold particles to human hepatocytes 
Human hepatocytes were incubated with 10 nm colloidal gold conjugated HBsAg to study 
the specific binding and uptake of HBsAg by electronmicroscopy. When Ell is involved 
in this process, incubation of hepatocytes with rabbit anti-EII IgG's prior to HBsAg-gold 
administration or preincubation of HBsAg-gold conjugate with anti-idiotypic (anti-HBsAg) 
antibodies before addition to the cells, should inhibit this binding. After incubation at 
4 eC, cells were washed and treated as described in materials and methods. The amount of 
gold particles per cell was determined under the experimental conditions and are repre­
sented in table 1. 
Table I. Mean number of gold particles attached per cell under different 
experimental conditions. Per experimental group 60 cells were ana­
lyzed per experimental group by 2 independent investigators and the 
average number of gold particles per cell were determined in 3 
experiments (Wilcoxson lest, ρ < 0.005). 
IgG's used in 
the incubation 
NIS 
anti-EII 
anti-HBsAg 
Gold particles 
bound per cell (+ SD) 
28 ± 6.6 
12.5 ± 4.95 
3.5 ± 1.7 
Percentage of control 
100% 
44% 
12.5% I 
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Cells incubated with gold conjugated HBsAg in the presence of NIS displayed the highest 
labelling density (28 ± 6.6 gold particles/cell). After preincubation of the hepatocytes 
with anti-EII IgG's (5/ig/ml) the number of gold particles per cell was significantly 
reduced by 66% (12.5±4.95 gold particles/cell). When the HBsAg-gold was preincubated 
with anti-idiotypic antibodies (8/ig/ml), the binding to the hepatocytes was inhibited by 
87% (3.5±1.7 gold particles/cell) as compared to results when experiments were 
performed using NIS IgG's (14/xg/ml). 
Internalization of the HBsAg-gold 
The results of internalization of gold conjugated HBsAg are shown in figure 2. After 
incubation at 4° С the HBsAg-gold particles are found to be attached to the plasma 
membrane of the hepatocytes (figure 2A). In figure 2D binding of HBsAg-gold to a 
typical coated pit region is shown. Warming of the cells at 37°C resulted in invagination 
of this region (figure 2B and 2E). After 5 minutes of incubation at 37°C endocytotic 
vesicles containing gold particles could be observed (figure 2C and 2F), indicating that 
internalization took place within a few minutes. When cells were incubated for 30 minutes 
at 37°C, virtually no gold conjugated HBsAg could be detected on the surface of the 
plasma membrane, indicating that bound HBsAg was internalized. 
Discussion 
It is generally accepted that surface proteins of enveloped viruses like HBV, interact with 
specific components on the plasma membrane of a susceptible host cell to enable the 
viruses to gain entry into these cells (7). In the case of HBV, the HBsAg envelope 
proteins should be considered to be important for such interaction and a specific HBsAg 
binding protein has in fact been identified in human liver (3). 
Electronmicroscopy is an elegant method for visualization of the binding and uptake of a 
ligand by its specific receptor protein. In this study, HBsAg conjugated to 10 nm 
49 
CHAPTER 2 
Figure 2. Binding and internalization of HBsAg conjugated to 10 nm colloidal gold by 
human hepatocytes. Cells were incubated with HBsAg-gold for 2hrs at 4°C and 
subsequently warmed to 37°C for 0 (panel A and D), 5 (panel В, С and E) and 
10 (panel F) minutes. The bars represent IO2 urn. The bar in panel D is indica­
tive for panel Α-D. The bar in panel F for panel E and F. 
colloidal gold was used to investigate whether EH is involved in the binding and uptake of 
HBsAg by human hepatocytes. Binding of HBsAg-gold to human hepatocytes could 
specifically be inhibited by incubation with rabbit anti-EII or with anti-idiotypic (anti-
HBsAg) IgG's. The results obtained from binding studies using radio-labelled ligand, 
shown in figure 1, were consistent with those of HBsAg-gold particles (Table I). The use 
of HBsAg-gold can therefore be considered as a suitable method for studying the specific 
binding and internalization of HBV envelope proteins. 
In the present study we showed that invagination of the coated pit region occurred at the 
HBsAg-gold binding sites, after warming of the cells (Figure 2). Moreover, the coated pit 
region was pinched off and led to the formation of endosomes containing HBsAg-gold. 
The process of invagination and formation of endocytotic vesicles takes place within a 
few minutes after warming of the cells. In the present study we also showed that rabbit 
anti-EII and anti-idiotypic (anti-HBsAg) could specifically inhibit the binding of HBsAg-
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gold to human hepatocytes and subsequent formation of endocytotic vesicles containing 
HBsAg-gold. Since it is generally accepted that coated pits play an important role in 
receptor mediated endocytosis of specific ligands (5, 8), our results strongly suggest that 
human liver endonexin II is actively involved in receptor mediated endocytosis of small 
HBsAg and indeed might be considered as HBV receptor. Further studies, analyzing the 
role of endonexin II in viral infection, are in progress. 
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CHAPTER 3 
Summary 
Hepatitis В virus (HBV) displays a distinct species and tissue tropism. Previously we have 
demonstrated that a human liver plasma membrane protein with a molecular weight of ap­
proximately 34kD specifically binds to HBsAg. This protein was identified as endonexin 
II (Eli), a Ca 2 + dependent phospholipid binding protein. Using a mouse monoclonal 
antibody, recognizing the HBsAg binding epitope on human Ell, liver tissue from various 
non-human species, human liver tissue and some extra-hepatic human tissues were 
screened for the presence of Ell. Using western blotting, EH was detectable in human, 
chimpanzee and rhesus monkey liver and in all tested extra-hepatic human tissues. In rat, 
mouse, cow and pork liver tissues Ell could not be detected with our antibody. Using 
immunohistochemical techniques the extra-hepatic localization of EH was confirmed. The 
distribution of Ell is restricted to a number of species, but is not tissue specific. The 
species tropism of hepatitis В virus therefore seems to be related to the species specificity 
of EH. Because Ell was detectable in all investigated human tissues, we concluded that 
EH alone does not account for the tissue specificity of HBV infections. 
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Introduction 
Hepatitis В virus (HBV) is a DNA virus of 42 nm that belongs to the hepadna virus 
family, which include Pekin duck, woodchuck, heron and ground/tree squirrel hepatitis 
viruses. These viruses all have a restricted host range and replication of the viruses is 
restricted to the livers of these species. HBV only infects humans and some non-human 
primates like chimpanzee and gibbon (1, IS, 20). 
The species and tissue tropism of HBV might be caused by: (1) the presence of a receptor 
molecule on human hepatocytes, which specifically interacts with HBV or (2) differential 
expression of HBV gene products in different cell types due to tissue-specific enhancers 
(12). Although replication of HBV predominantly occurs in the liver of infected patients, 
HBV DNA, transcripts and HBV antigens are also found in non-hepatic tissues like lym­
phocytes, pancreas, kidney, placenta, skin, gastrointestinal tract, gonad, thyroid and 
adrenal glands (14, 22, 23). Probably a combination of receptor mediated uptake and 
regulation of HBV expression by tissue-specific enhancers is responsible for the host- and 
tissue specificity of HBV infection. 
Recently we have identified a human liver plasma membrane protein with a molecular 
weight of approximately 34kD, which specifically binds to hepatitis В surface antigen. 
Amino acid sequence analysis resulted in the identification of this protein as endonexin Π 
(ΕΠ, 4). Ell belongs to the annexin family, a group of highly related phospholipid- and 
Ca2+ binding proteins. Its presence was earlier described in human placenta (6, 9). 
Annexins have the same general structure: a core formed by a four- or eightfold repeat of 
70 amino acids with a highly conserved 17 amino acid consensus sequence, containing the 
Ca2+- and phospholipid binding sites. The -NH2 termini of the annexins display a great 
divergency and determine the different functions of the proteins (2). The precise physiolo­
gical function of Ell has not yet been established, although the formation of Ca2+-
channels (18) and involvement in blood-coagulation (9) have been described in in vitro 
experiments. 
After purification of Ell from human liver tissue a rabbit polyclonal antiserum to Ell was 
raised. Several weeks after immunization of the rabbits anti-idiotypic antibodies against 
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HBsAg were detected in the antiserum. This indicates that a relationship between these 
proteins must exist (5). In this paper we studied the hepatic distribution of EH in rat, 
mouse, cow, pork, chimpanzee and rhesus monkey and in non-hepatic human tissues like 
ileum, lung, kidney, placenta, lymfocytes and stomach to gain more insight in the 
involvement of EH in species and tissue tropism of HBV. 
Materials and methods 
Tissues 
Human liver tissue was obtained from organ donors, other human tissues were obtained 
by surgery or endoscopy. The investigations were approved by the local committee on 
human experimentations. Animal liver tissues were obtained via the Central Laboratory 
Animal Centre (University of Nijmegen, The Netherlands). All tissues were kept at 4 °C, 
cut into 1 cm3 pieces, rapidly frozen in liquid nitrogen and stored at -80 °C prior to use. 
The tissues were diluted 5 times with cold homogenization buffer (0.25 M saccharose, 20 
mM Tris.HCl pH 7.4, 1 mM dithiotreitol (Sigma Chemie, Brussels, Belgium)) and 
homogenized on ice using a dounce homogenizer. Cellular debris and nuclei were 
removed by centrifugation for 15 minutes at 1,000 g. The supernatant was centrifuged for 
20 minutes at 9,000 g to obtain a plasma membrane enriched fraction (P9). The 9,000 g 
supernatant was centrifuged at 150,000 g for 1 hour (hr) to obtain the cytosolic super-
natant (S150) and the microsomal pellet (P150), which is enriched with endoplasmatic 
reticulum (16). All handlings were performed at 4 C. Protein concentrations in the 
different fractions were measured according to the method of Lowry et al. (13). 
Immunoblotting 
100 /ig of protein was size separated on a 11 % SDS Polyacrylamide gel (PAGE). The 
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proteins were blotted onto nitrocellulose filters (Schleicher & Schuell, Dassel, Germany) 
using a semi-dry blotting system (Novablot, Pharmacia, Upsala, Sweden). Aspecific bin-
ding was blocked with 1% gelatin in phosphate buffered saline with 0.05% Tween 
(PBST). The blot was incubated overnight with a 1:500 dilution of monoclonal mouse 
anti-EII (Mab), recognizing the HBsAg binding epitope of Ell, in blocking buffer. The 
production and characterization of the monoclonal antibody will be described elsewhere. 
Specific binding was detected after a 1 hr incubation with 1:100 diluted peroxidase-
conjugated rabbit anti-mouse antibody (rampo, Dakopatts, Glostrup, Denmark) using 
0.06% 3.3'diaminobenzidine (DAB, Sigma) in 0.05 M Tris.HCl (pH 7.6)/ 0.03% Cobalt 
chloride (7) as staining reagent. 
Immunohistochemical localization of £11 
Human liver placenta, ileum, stomach, kidney and lung tissues were fixed in 4% formalin 
and embedded in paraffine. After rehydration of the sections, endogenous peroxidase 
activity was blocked by incubation for 10 min with methanol/3% H202. Aspecific binding 
was blocked by incubation in 4% bovine serum albumin (BSA, Boehringer (Mannheim, 
Germany) in PBST for 30 min at RT. The sections were incubated o/n with 1:500 diluted 
anti-EII Mab in 4%BSA/PBST at 4 °C. After 1 hr incubation with 1:100 diluted rampo 
and colour development was performed with 0.1% DAB/0.01% H202 in PBS. The tissue 
sections were counterstained with haematoxylin, dehydrated and permanently mounted. 
Incubation with 1:100 diluted pre-immune serum was used as negative control. 
Results 
Species specificity of Ell 
Rhesus monkey, chimpanzee, mouse, rat, cow and pork liver were homogenized and 
fractionated as described. The plasma membrane enriched (P9), the cytosolic (S150) and 
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the ER enriched fractions (P150) were examined on immunoblot for the presence of 
Figure 1. Immunoblot of 100 ug of protein from the P9 (a), SI50 (b), P150 
(c) of rhesus monkey (I), rat (2), chimpanzee (3), mouse (4), 
porcine (5) and bovine (6) liver. EH (250ng) isolated from human 
liver, was used as marker (m). 
Ell. The results are shown in Figure 1. Ell isolated from human liver as described 
elsewhere (4) was used as marker. In addition to human liver, only in livers of rhesus 
monkey and chimpanzee Ell could be detected with our antiserum. The highest content of 
Ell was present in the P9 and the P150 membrane fractions respectively. 
Tissue specificity of Ell 
The presence of Ell in kidney, lung, stomach, ileum and placenta was also investigated 
on immunoblot. Results are shown in Figure 2. All human tissues examined gave positive 
staining for Ell, although some variation in expression levels was observed. 
Again Ell predominantly occurs in the P9 and P150 membrane enriched fractions of the 
examined tissues, which is in agreement with the previous results in rhesus monkey and 
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Figure 2. lmmunoblot of 100 μg protein from P9 (a), S150 (b) and P150 (c) 
from human kidney (I), lung (2), stomach (3), ileum (4) and pla­
centa (5). Native Ell from human liver tissue was used as marker 
(m). 
chimpanzee liver (figure 1). 
Immunohistochemical localization of Ell 
On the immunoblot all human tissues examined were positive for Ell. The presence of 
this protein in human placenta and lymphocytes was already described ((, 17). In an 
immunohistochemical study human placenta was therefore used as a positive control. 
Incubation of placenta tissue sections with monoclonal mouse anti-EII resulted in the 
staining of syncytiothrofoblasts, the stroma and stromal cells (Figure 4A). Since rat liver 
homogenates did not react with our antibody, rat liver tissue was used as negative control 
(Figure 4B). Incubations with pre-immune serum was used as second negative con-
trol(results not shown). The results of the immuno-histochemical study of human liver 
tissue and the different non-hepatic human tissues with anti-EII are respectively shown in 
figure 3 and 4. 
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Figure 3. Immuno-hislochemical localization of Ell in human liver tissue. Incubation with non­
immune mouse serum was used as negative control (A). In panel В positive staining of the 
hepatocyte membrane (H) and kupffer cells (K) are indicated. In panel С presence of Ell 
in bile duct epithelium (B) and stroma with stromal cells (S) are shown. The bar 
represents 1 μ/η. 
In human liver endonexin II could be detected in the bile duct epithelial cells (Figure 3C), 
stroma and stromal fibroblasts of the portal triangles (Figure 3C), kupffer cells (Figure 
3B), and in the hepatocytes. The bile duct epithelial and kupffer cells were totally stained, 
whereas the staining in the hepatocytes was restricted to the plasma membrane. 
In the fundus of the human stomach (Figure 4C) EH was demonstrated in the fibroblasts 
of the lamina propia, mucous cells, the chief cells of the glands and in the muscularis mu­
cosae. The parietal cells didn't react with our antibody. In the tissue sections of human 
ileum (Figure 4D) Ell could be detected in the goblet cells, stromal fibroblasts, inflamma­
tory cells of the lamina propia and the muscularis mucosae (not shown). In human kidney 
tissue EH was detected in the visceral epithelium of the glomeruli (Figure 4E). In human 
lung tissue positive staining for Ell was seen in the epithelium of the terminal bronchioli 
in intra-alveolar macrophages. 
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Figure 4. Immuno-histochemical localization of Ell in human placenta (A), rat liver (B), stomach (C), ileum (D), kidney 
(E), lung (F). In panel A the syncythiothrofoblasts (1), stroma and stromal cells (2) are marked. In panel С 
and D stromal fibroblasts and inflammatory cells are indicated (2). In panel С mucous cells (1), parietal cells 
(3) and chief celL· (4) are marked. In panel E the visceral epithelium of the glomeruli is indicated. In panel F 
epithelium of the bronchioli are indicated. The bar represents I μm. 
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Discussion 
In a previous paper we have demonstrated that a 34kD liver membrane protein specifi­
cally binds to HBsAg. This protein is present in human liver but not in rat liver (4). 
Amino acid sequence analysis resulted in the identification of this HBsAg binding protein 
as Ell (4). A monoclonal antibody against the HBsAg binding epitope of human liver Ell 
(will be described elsewhere) was raised in mice and this Mab was also used to screen 
livers of different species and several extra-hepatic human tissues for the presence of Ell 
to get more insight in the role of Ell in the species- and hepatotropism of HBV. On 
immunoblot ΕΠ could be demonstrated in human, chimpanzee and rhesus monkey liver, 
but was not detectable in rat, mouse, cow and pork liver. Human Ell displays 92% and 
64% homology with rat and bovine Ell respectively (6, 9). Despite this high degree of 
homology rat and cow liver homogenates did not react with our Mab. 
Membrane preparations of human liver, kidney, lymphocytes and fibroblasts were all able 
to bind HBsAg (11) and homogenates of these tissue also reacted with the Mab. More­
over, the Mab competed with HBsAg for the binding to Ell (personal communi-cation). 
These results indicate that the Mab specifically recognizes HBsAg binding epitopes on 
Ell. 
Cow, pork, mouse and rat can not be successfully infected with HBV and in the livers of 
these species no Ell could be demonstrated with the Mab. In human and chimpanzee 
liver, Ell was detected and both species are susceptible hosts for the HBV. Rhesus 
monkey (Macaca mulata (Figure 1)) and Java monkey (Macaca fascularìs) (result not 
shown) liver samples also reacted with the Mab and membrane fractions of these liver 
tissues were able to bind HBsAg specifically (result not shown), indicating that EH is 
present. Recently the results of succesfull HBV infections in Macaca Speciosa, Macaca 
Assemensis and Nycticebus Cougang were described (3), indicating that Ell will probably 
also be present in these species. The host range of HBV therefore seems to be correlated 
to the species specific expression of the HBsAg binding protein, EIL 
AU human tissues examined in this study contain measurable amounts of EIL Ell was 
predominantly present in the membrane enriched fractions (P9 and Ρ150) of the tissue 
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homogenates. Using immunohistochemistry the mebrane associated localization of EH in 
human liver tissue was confirmed (Figure 3). The amino acid- and cDNA sequence of 
human liver Ell is identical to that of placenta and lymphocytes (4, 9, 17). Apart from 
these tissues, Ell was also present in human lung, ileum, stomach and kidney. To be sure 
that the results found on immunoblot were not caused by infiltrated lymphocytes, the 
tissues were also examined immunohistochemically. In all tissues expression of Ell was 
detected in different cell types (Figure 3+4). For rat Eli a similar distribution pattern in 
rat tissues was described (10). 
The tissue specific expression of HBV, which predominantly replicates in the liver, does 
not correlate with liver specificity of Ell. Since the hepatotropism of HBV is not related 
to the presence of Ell, the explanation for this phenomenon must be found in tissue 
specific replication of HBV, due to the modulating role of tissue specific enhancer 
elements (8, 19, 21). Mason et al. (14) investigated the presence of HBV DNA, tran-
scripts and antigens in patients, which died with a chronic HBV infection. All cell types 
in which HBV was detectable, were positive for Ell in our study. The extra-hepatic 
occurrence of HBV DNA, transcripts and antigens might therefore be explained by the 
presence of Ell in non-hepatic tissues. 
Although presence of EH may be indispensable for HBV to gain entry into a cell, it is 
certainly not the only determinant needed for a successful HBV infection. 
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Summary 
Endonexin II (EH) present on the surface of human hepatocytes, has recently been 
identified as a hepatitis В surface antigen (HBsAg) binding protein. Ell is a Ca2+-depen-
dent phospholipid binding protein with a molecular weight of 34 kilodaltons. A full length 
cDNA clone, encoding human ЕП was isolated from a human liver cDNA library and 
was placed under the control of the polyhedrin promoter of Auiographa califomica 
nuclear polyhedrosis virus (AcNPV). Infection of Spodoptera frugiperda (Sf9) cells with 
the resulting recombinant baculovirus yielded high amounts of recombinant ЕП. This 
protein has the same molecular weight and isoelectric point as native human Ell and can 
be easily purified by methods, analogous to those described for the native protein. 
Moreover, the recombinant protein, like native Ell, binds specifically to HBsAg. 
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Introduction 
Although much is known about the structure of the hepatitis В virus, its genome and the 
regulatory elements involved in viral DNA transcription (11, 21), little is known about 
the initial steps of HBV infection. A main cause for this lack of knowledge is the inability 
of the virus to infect cells, other than human or certain non-human primate liver cells in 
vitro. HBV has a strict host- and tissue specificity. The tissue specificity might be caused 
by the need for liver specific factors for the activation of the various viral promoters and 
enhancers (1, 24, 25). Another cause for host and tissue tropism might also be the 
existence of a specific receptor on the surface of the human hepatocyte, which interacts 
with the virus envelope proteins, enabling viral entry into liver cell. The existence of 
specific receptors for viruses is not unknown in virology (23). It can even be the sole 
determinant of viral tropism. One possible mechanism for vaccination and treatment of 
viral hepatitis B, could be the prevention of viral entry into the liver cell, by blocking the 
interaction of the receptor and the viral surface proteins. The localization of the receptor 
binding site on the hepatitis В surface protein (HBsAg) has been the subject of many 
investigations. The importance of the PreSl sequences in for the attachment of HBV to 
the human hepatocyte has been mentioned several times (3, 12, 17, 18, 20), but a specific 
PreSl binding liver protein has not been identified so far. In contrast, a specific small 
HBsAg binding protein was demonstrable on intact human liver cells. Recently we 
identified this small HBsAg binding protein as human liver endonexin Π (EII)(6). ΕΠ 
belongs to the annexins, a group of highly related proteins, that all bind to phospholipids 
in a Ca2+ dependent way. The annexins, with molecular weights ranging from 32-67 
kilodaltons (2, 9), have the same overall structure. The core of these proteins is formed 
by a four- or eight fold repeat of a 70 amino acid sequence, with a highly conserved 17 
amino acid region, containing the Ca2+- and phospholipid binding properties. 
For further research on the involvement of Ell in HBV infection and for the localization 
of the exact binding epitopes on the viral surface proteins and on the receptor itself, large 
amounts of purified protein are generally required. For this purpose Ell cDNA was 
isolated from a human liver cDNA library. This cDNA was cloned in the well charac-
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terízed baculovirus expression system (15,19). The recombinant Ell is produced in high 
amounts, is easy to purify and has the same HBsAg binding properties as the native 
protein. 
We therefore consider this recombinant protein to be an important tool in future hepatitis 
В research. 
Materials and methods 
Screening of cDNA library for ЕП 
Using amino acid sequence information from the HBsAg binding protein (6) the 36-mer 
5'-TTTTTCATTTGTTCCAGCTCCCTTCAAGGCATGTTT-3' was synthesized on an 
Perkin Elmer DNA synthesizer. This oligonucleotide was labelled with 32P-ATP using T4-
polynucleotide kinase (Life Technologies) according to the manufacturers instructions. A 
human liver cDNA library in phage lambda-ZAP (a kind gift from dr. Lamers, Academ­
ical Medical Center, Amsterdam) was screened with this probe using standard plaque 
lifting and hybridization techniques. cDNA inserts were rescued from these clones by co-
infection of E.Coli JM109 cells with the concerning recombinant phage-lambda-ZAP and 
helper phage R408. Recombination events lead to the formation of the plasmid 
pBluescript, containing the cDNA inserts in the EcoRl site of its polylinker. 
DNA manipulations 
DNA manipulations were carried out essentially according to standard procedures (16). 
Restriction enzymes and other DNA-modifying enzymes were purchased from Life 
Technologies. High temperature DNA sequencing was performed using a Taq-polymerase 
based kit (Promega) according to the manufacturers instructions. Electrophoresis of the 
reaction products was performed in 7% acrylamide/7 M urea gels under standard con­
ditions (Life technologies SA-100 system). 
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Cells and viruses 
Spodoptera frugiperda (Sf9) cells were grown as monolayer cultures at 27 °C in TC100 
medium (Life technologies), supplemented with 10% foetal calf serum (FCS) and 40 
μg/ml gentamycin. Seeding of the cells and subsequent virus infections were performed as 
described by Summers and Smith (22). 
Construction of baculovirus transfervectors pVLendo-1.4AE and pVLendo-1.4EE 
The cDNA inserts were purified from pBluescript by digestion with EcoRl, electro­
phoresis on 0.6% agarose gels and electro-elution using a biotrap apparatus (Schleicher & 
Schuil). 116 of the 150 non-coding nucleotides at the 5'-terminus (figure 1) were removed 
by digestion at a unique Avail site in the Ell cDNA, 34 nucleotides upstream from the 
start codon. From this Avall-EcoRl fragment and the original EcoRl-EcoRl fragment, 
the termini were made blunt using T4-DNA polymerase (Life Technologies) and the 
resulting blunt fragments were ligated in the dephosphorylated Smal site of pGEM3Zf[-] 
(Promega) resulting in pGEMendo-1.4AE (1.4 kb Avall-EcoRl fragment) and pGEM-
endo-1.5EE (1.5 Kb EcoRl-EcoRl fragment). The internal Hindlll restriction site (at 
nucleotide 1310) was used to select for plasmids, containing the insert in the correct 
orientation for future expression. One pGEM-endo vector, containing the 1.4 Kb Avall-
EcoRl fragment in the wrong orientation, was used as a negative control for later 
infection (pGEMendo-1.4EA). The pGEM-endo vectors were digested with BamHl and 
Kpnl and cDNA inserts were purified by agarose gel electrophoresis and electro-elution. 
From the baculovirus transfer vector pVL941 a 535 bp BamHl-Kpnl polyhedrin fragment 
was removed and kept for later use in recombinant virus purification. This fragment was 
replaced by the EH encoding BamHl-Kpnl fragments, purified from the pGEM-endo 
plasmids, resulting in pVLendo-1.5EE, pVLendo-1.4AE and pVLendo-1.4EA. 
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Cotransfection and purification of recombinant baculovirus 
To introduce the ΕΠ cDNA in the baculovirus genome, pVLendo plasmids and wild type 
Autographe califomica nuclear polyhedrosis virus (AcNPV) DNA were cotransfected in 
Sf9 cells. 2x10* S19 cells were seeded in a 25 cm2 culture flask (Costar). After 3 hrs, cell 
monolayers were washed three times with serum-free SF900 medium (Life Technologies) 
to remove traces of FCS. 2 μg pVLendo and 1 μζ AcNPV DNA in sterile water (40 μΐ) 
was mixed with 40 μΐ (10 μg) of lipofectin reagent (Life Technologies) and left to stand 
for 15 min at room temperature. The resulting DNA-liposome complex was diluted with 2 
ml SF900 medium and added dropwise to the cells. After overnight transfection, the cells 
were washed once with and cultured in TC100 medium, supplemented with 10% FCS and 
40 jig/ml gentamycin. 
Purification of the recombinant baculovirus was performed as described by Kos et al. 
(10), using dotblot assays under standard conditions with Î2P labelled 1.4kb EH cDNA. 
Culture media from positive wells were used in a 10* fold dilution to infect SÍ9 cells 
cultured in 75 cm2 culture flasks, containing 2xl06 Sf9 cells. Cells were harvested three 
days p.i. A fraction of the homogenate was lysed in NaOH, neutralized and spotted on 
nitrocellulose. Hybridization with the 535 bp BamHl-Kpnl polyhedrin gene fragment was 
performed to test for the presence of wild type AcNPV. Supernatants were used as virus 
stocks and stored at 4 °C for immediate use and at -80 °C for long term storage. The titre 
of these virus stocks was determined by serial dilutions in a dot blot assay. 
Nomenclature for the recombinant viruses was Acendo-1.5EE, Acendo-1.4AE and Acen-
do-1.4EA, according to the previous used nomenclature for the various plasmids. 
bo-electric focusing, SDS-polyacrylamidegel electrophoresis and Western blotting 
To analyze recombinant cells for production of Ell, cells were homogenized in buffer H 
(20 mM HEPES pH 7.4, 150 mM KCl, 2 mM MgCl2, 0.1 mM phenyl-methyl-sulfonyl 
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fluoride) using a glass-glass Potter Elvehjem. 20 μg of protein was boiled in SDS-PAGE 
sample buffer and proteins were electrophoresed on 10% Polyacrylamide gels. Semi-dry 
EcoRI Endonexin II cDNA 
—+-—^^^^^^^Ш pVI_endo-1.5EE 
Avail 
-t-L^H 
EcoRI 
^ ^ ^ 
EcoRI 
^ ^ ^ | pVLendo-1.4AE 
Avail 
^ ^ ^ н _ І pVI_endo-1.4AE 
^ Ф polyhedrin promoter 
Figure 1. Besides the complete cDNA fragment, an Avall-EcoRl fragment 
lacking 135 5'-terminal non-coding nucleotides was cloned in 
pVL941 in order to minimalize the distance between promoter and 
initiation codon. The resulting transfervectors are: pVLendo-l.SEE 
(1.5 lib EcoRI-EcoRI fragment in coding orientation); pVLendo-
1.4AE (1.4 kb Avall-EcoRl fragment in coding orientation); 
pVLendo-1.4EA (1.4 kb Avall-EcoRl fragment in non-coding 
orientation, as a control). 
western blotting was performed on a Novablot apparatus (Pharmacia) under standard 
conditions. Immunoblots were incubated during 1 hr at room temperature with blocking 
buffer (phosphate buffered saline pH7.4, 0.05% Tween-20, 1% gelatine). Subsequently 
the blots were incubated overnight with a 1:5000 dilution of a rabbit anti-human liver ЕП 
(7). Bound antibodies were detected by a 2 hrs incubation with peroxidase-conjugated 
Swine-anti rabbit immunoglobulin (1:800, Dakopatts) and colour development in 50 raM 
Tris, pH7.6, 0.06% diaminobenzidine, 0.03% Cobalt chloride (CoClj). 
Isc-electric focusing was performed on pre-cast ampholine pH gradient gels in a Phast-
System apparatus (Pharmacia, Uppsala, Sweden), followed by staining with Coomassie 
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Tris, pH7.6, 0.06% diaminobenzidine, 0.03% Cobalt chloride (CoCy. 
Iso-electric focusing was performed on pre-cast ampholine pH gradient gels in a Phast-
System apparatus (Pharmacia, Uppsala, Sweden), followed by staining with Coomassie 
Brilliant Blue (CBB). pH markers in the range 3-10 were from the same manufacturer. 
Immunocytochemical studies on Sf9 cells, infected with recombinant virus 
100,000 Sf9 cells were seeded in 4 wells plates (Costar) with glass cover slips and 
allowed to attach for 2 hrs. The cells were infected with wild type or recombinant virus 
with a multiplication of infection (moi) of 1. Cells were washed with phosphate buffered 
saline (PBS) and fixed with ice-cold methanol at 1, 2, 3 and 4 days post infection. After 
drying, cells were stored at -20°C until analysis. Cells were thawed in ice-cold methanol 
and washed in PBS. Endogenous peroxidase activity was blocked by a 10 min incubation 
with methanol/3 %H2Cv Aspecific binding sites were blocked in PBS containing 0.05% 
Tween-20, 0.1% Triton-XlOO, 4% BSA (PBSTTB). The cells were incubated overnight at 
4°C with a 1:1500 dilution of a polyclonal rabbit anti-human liver EH in PBSTTB. After 
extensive washing with PBS-0.05% Tween-20 (PBST), 1:40 diluted peroxidase conjugated 
swine anti rabbit antibodies in PBSTTB was added. After 1 hr, cells were washed in 
PBST. Peroxidase was visualized by reaction with 0.1% diaminobenzidine in PBS with 
0.3% H202 for ten minutes. Cells were counterstained with haematoxylin, dehydrated, 
mounted permanently and examined by lightmicroscopy. 
Isolation and purification of recombinant Ell 
Sf9 cells were seeded in 160 cm2 tissue culture flasks and infected with baculovirus Ac-
endo-1.4AE with a moi of 5. Four days post infection cells were harvested. After 
centrifugation, the cells were homogenized in buffer H using a glass-glass Potter 
(Elvehjem). Nuclei and unbroken cells were pelleted at 800xg. CaCl2 was added to the 
supernatant to a final concentration of 1 mM and recEII was isolated using calcium 
precipitation according to the procedures for native Ell (5, 6). However, in the first 
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100,000 g centrifugation step, large amounts of Eli are not co-pelleted with Ca2+ and 
phospholipids. The supernatant from this step was mixed with the phospholipid pellet 
from which Ell had been released in the previous EGTA centrifugation step. This 
suspension was supplemented with Ca2* and left to stand on ice for 1 hr to enable new 
complexes to be formed. After centrifugation, Ell was again released by EGTA treat­
ment. After repeating this procedure three times, most of the ΕΠ is precipitated and the 
yield is maximal. Finally, EGTA supernatants containing the recombinant protein were 
pooled and stored frozen. 
Radio-labelling of proteins 
5 /xg of recombinant endonexin II was labelled with Na125I (Amersham, Buckinghamshire, 
UK) using Iodogen (l,3,4,6-tetrachloro-3a-6o-diphenylglycoluril, Pierce, Rockford, IL 
USA) as a catalyst according to the manufacturers prescription. 
Binding of recombinant endonexin Π to HBsAg 
To test the functional activity of the recombinant protein, binding studies were carried out 
as described (6). Small, middle and large HBsAg were coated on micro titre dishes 
(Greiner) and incubated with radio-labelled recombinant endonexin II in PBS containing 
2mM CaCl2 and MgCl2 (PBS/Ca/Mg). The wells were washed with PBS/Ca/Mg. Bound 
protein was released by adding PAGE sample buffer to the wells. Released proteins were 
denatured at 100 °C for 5 min and subjected to SDS-PAGE and autoradiography. 
In parallel experiments, after the incubation with recombinant endonexin II, the nonrever­
sible cross-linking agent Disuccimidylsuberate (DSS, Pierce) in dimethylsulfoxide 
(DMSO) was added in a final concentration of 1 mM. After crosslinking for 30 min at 4 
°C, 100 mM glycine was added to stop the reaction. Formed complexes were released in 
SDS-PAGE sample buffer and subjected to SDS-PAGE and autoradiography. 
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Results 
Isolation and cloning of Ell encoding cDNA 
In order to isolate cDNA, encoding human Ell, a human liver cDNA library in phage 
Lambda ZAP was screened with specific "P-labelled synthetic oligonucleotides. Five 
independent clones were picked from this library and plaque purified, and their identity 
was reconfirmed by positive hybridization of the purified plaques to a second Ell-specific 
oligomer (results not shown). The inserts were rescued by helper phage R408 to yield the 
plasmid pBluescript with the cDNA fragment in the Eco RI restriction site of the multiple 
cloning site. 
All five clones were identical and contained full length cDNA inserts of approximately 
1470 base pairs as was determined by DNA sequencing (results not shown). The cDNA 
sequences of these clones contained intact start and stop codons and were identical to the 
published sequence of human placental Ell, including 5' and 3' non-coding regions (8). 
One of the cDNA's was cloned in the baculovirus transfer vector pVL941 to yield the 
pVLendo vectors as described in materials and methods. 
The Ell cDNA contains a 150 bp non-coding region at its 5'-terminus. Because a large 
distance between promoter and initiation codon might have a negative effect on the 
efficiency of the promoter, most of this region was removed by digesting the cDNA at a 
unique Avail site, 34 base pairs upstream from the initiation codon. The resulting Avall-
EcoRl and the EcoRl-EcoRl fragments were cloned in pVL941 to yield pVLendo-
1.4AE, pVLendo-1.5EE and pVLendo-1.4EA (non-coding orientation of Avall-EcoRl 
fragment, functioning as a control). The result of this procedure is the replacement of part 
of the polyhedrin gene in pVL941 by Ell cDNA, which is thus placed under the control 
of the very efficient polyhedrin promoter. The original polyhedrin ATG start codon in 
pVL941 has been changed by site directed mutagenesis to a non-sense ATT codon (14). 
When the pVLendo transfervectors are cotransfected with wild type AcNPV DNA in Sf9 
cells, homologous recombination occurs with a frequency of 1-5% at a site near the 
polyhedrin gene, resulting in the integration of the Ell cDNA in the AcNPV genome. In 
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this process, the wild-type polyhedrin initiation codon is replaced by the mutated ATT 
codon from pVL941. So, for translation of recombinant RNA the start codon of the 
cloned gene is used. The recombinant protein is thus not produced as a fusion protein 
which means that it will have the best possible resemblance to the native protein. 
After cotransfection of the transfervectors pVLendo-l.SEE, pVLendo-1.4AE and pVL-
endo-1.4EA with wild type AcNPV DNA, recombinant virus was purified from wild type 
AcNPV to yield respectively Acendo-1.5EE, Acendo-1.4AE and Acendo-1.4EA. After 
three rounds of purification, cells were free of wild type baculovirus. The titre of 
recombinant virus in the supernatant, as determined by infection of Sf9 cells in 96-wells 
culture dishes with serial dilutions of virus stock, was approximately 107/ml. 
SDS-PAGE and Western blotting of recombinant Sf9 cells 
To test infected cells for recombinant protein production, whole cell lysates were 
prepared from 50,000 cells and subjected to SDS-PAGE and Western blotting. Figure 2 
shows a CBB stained Polyacrylamide gel (figure 2A) and the corresponding Western blot 
of cells, infected with Acendo-1.5EE (lanes 1), Acendol.4AE (lanes 2) and Acendo-
1.4EA (lanes 3). Using laser densitometry on the Western blots, we estimated that at least 
8 mg of recombinant protein is produced by 5x10" Sf9 cells, infected with Acendo-
1.4AE. As expected, the removal of the 135 bp at the 5'-noncoding region led to a 
significant increase of Ell expression (compare lanes 1 and 2). 
Iso-electric focusing and SDS-PAGE of recombinant Ell, revealed that the iso-electric 
point and molecular weight are identical to that of native Ell (figure ЗА and 3B, compare 
lanes 2 and 3). 
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Figure 2. SDS-PAGE and Western blotting of recombinant Ell. 
3 days after infection with Acendo-1.5EE flanes 1), 
Acendo-1.4AE (lanes 2) or Acendo-1.4 EA (lanes 3), 
Sf9 cells were lysed in SDS-PAGE sample buffer. 
Panel A represents a Coommassie Brilliant Blue 
stained 10% Polyacrylamide gel, panel В the con­
comitant Western blot, stained with rabbit-anti human 
Ell. Arrow indicates the position of the 34 kD protein. 
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Figure 3. Comparison of recombinant and native Ell concerning molecular 
weight and iso-electric point. Panel A: Phast System SDS-PAGE 
gradient gel (8-25% Polyacrylamide). Lane 1 and 4 (M): the Mw 
markers 92, 68, 45, 29, 21 and 14 kD; lane 2: purified recombi­
nant Ell; lane 3: purified native Ell. Panel B: Phast System IEF gel 
pH 4-6.8. Lane 3 (M): pH markers pi 9.3, 8.65, 8.45, 8.15, 7.35, 
6.85, 6.55, 5.85, 5.20, 4.55, 3.5, lane 1: recombinant EU; lane 2: 
native EH. Both gels were stained with CBB following the manu­
facturers instructions. 
Immunocytochemical studies on infected Sf9 cells 
Immunocytochemical studies were performed to investigate the localization of the 
recombinant Ell in infected Sf9 cells. The results are shown in figure 4. AcNPV infected 
Sf9 cells do not react with anti-EII (panel F, note the high amounts of polyhedrin 
produced (arrow)). On Sf9 cells, infected with Acendo-1.4EA also no reaction was seen 
(results not shown). Rabbit pre-immune serum did not react with Acendo-1.4AE infected 
cells (results not shown). From 1 to 3 days post infection (p.i.) gradually more cells are 
producing membrane bound Ell (panels A-C). 4 days p.i., the recombinant Ell starts to 
accumulate in the cytoplasm (panel D). At 5 days p.i. most cells detach from the 
monolayer and burst (panel E, arrow figure 6 indicates leakage of recombinant protein). 
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Figure 4. lmmunoperoxidase staining of infected recombinant Sf9 celh. Sf9 celb were infected 
with Acendo-IAAE, fixed and stained with anti-Ell as stated in Materials and Methods. 
Panel A-E: 1-5 days post infection, panel F: wild-type AcNPV infected Sf9 cells. The 
arrow in panel E shows leakage of recombinant protein, the arrow in panel F points at 
polyhedrin accumulations. 
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Isolation and purification of recombinant human ΕΠ 
From SDS-PAGE and immunoperoxidase staining of infected cells, it is obvious that at 
day 4 p.i. more than 90% of cells are infected and the production of recombinant Ell is 
optimal. Although there is some loss of recombinant ΕΠ the culture medium (due to lysed 
cells), cells at this stage of infection were used to isolate recombinant protein. 
To purify the recombinant Ell, a modified version for the purification of Ell from human 
placenta as previously published was used (5). This procedure is based on the phospholi­
pid binding properties of Ell in the presence of Ca2+. After pelleting a phospholi-
pid/Ca2+/EII complex, Ell is released from this complex when incubated with 
ethylenebis(oxyethylenenitrilo)tetraacetatic acid (EGTA). This procedure is also applicable 
to recombinant Sf9 cells, as shown on the western blot in figure 5. Lane 1 contains 20 μg 
of total homogenate protein of Sf9 cells, infected with Acendo-1.4AE. After removal of 
nuclei and precipitation with Ca2+, the pellet contains Ell Qzne 2), which is released in 
the supernatant after incubation with EGTA (lane 4). However, lane 3 shows that 
considerable amounts of recombinant Ell can not be precipitated with Ca2+ (considering 
that the volume of the supernatant was approximately 20 times the volume of the 
resuspended pellet). This is probably due to the large excess of recombinant protein as 
compared to the amount of phospholipids present. 
To purify this non-precipitable protein, the Ca2+ precipitation was repeated twice using 
the phospholipid pellet from the first precipitation step after it had been cleared from ΕΠ 
with EGTA (lane 5 and 6 respectively). The pooled EGTA supematants contained only 
one protein band on SDS and IEF gels (Figure 3, lanes 2). 
Recombinant ΕΠ binds very efficiently to HBsAg 
Purified recombinant Ell was labelled with l 2 5I using the Iodogen method to a specific 
activity of 4 χ 107 cpm//xg protein. This radio-labelled preparation, consisting of only one 
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Figure 5. Western blot, stained with rabbit anti-human Ell, illustrating 
isolation and purification of recombinant Ell. Recombinant Ell was 
isolated from Acendo-1.4AE infected Sf9 cells using its property as 
a Ca2*-dependent phospholipid binding protein. Every lane contains 
2 μg of protein. Lane 1 shows a total homogenate, lanes 2 the 
supernatant after EGTA treatment as described in Materials and 
Methods. After washing the phospholipid pellet twice with buffer H 
containing EGTA, negligible amounts of Ell are released (lanes 3). 
The washed pellet is however capable of renewed binding to Ell, as 
is shown in lanes 4 (after second round of binding and EGTA treat­
ment) and lanes 5 (after third round of binding and EGTA treat­
ment). Lanes 6 show, that there is still EH left in the supernatant, 
even after three rounds of incubation with phospholipids. 
protein band in SDS gels, was used in binding assays on HBsAg as described in Materials 
and Methods. Figure 6A shows the result of such a binding experiment on small HBsAg. 
It is clear from this autoradiogram that the binding of recombinant Ell to HBsAg is strict­
ly Ca2+- and Mg2+- dependent. When the incubation mixture contains no Ca2+, there is no 
binding at all (lanes 1 and 3). Addition of Ca2+ and Mg2+ drastically increases the amount 
of binding of Ell. Addition of only Ca2+ leads to a moderate binding. This same effect 
was observed when purified native Ell was used in a binding study (results not shown). 
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Figure 6. Functional activity of recombinant Ell. A) Ca2*- and Mg2*-depen-
dent binding of recombinant Ell to HBsAg. Radio-labelled recom-
binant Ell was added to solid-phase coated HBsAg as described in 
Materials and Methods. After incubation, bound Ell was released, 
subjected to SDS-PAGE and autoradiography. Binding assays of 
recombinant Ell on small HBsAg were performed in PBS (lane 1), 
PBS with Ca2* (lane 2), PBS with Mg2* (lane 3) and PBS with both 
Ca2* and Mg2* (lane 4). B) Binding of recombinant Ell to solid 
phase coated small HBsAg flanes 1), large HBsAg (lanes 2), preSl 
(lanes 3) and BSA (lanes 4) (all experiments in duplicate). 
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Figure 7. DSS crosslinking of recombinant Ell bound to small 
HBsAg. Lane 1: no crosslinker added; lanes 2 and 3: 
DSS added (duplicate experiment). Arrows represent 
molecular weight markers: Downward 92 kD, 68 kD, 
45 kD and 29 kD. 
Figure 8B shows the results of a binding experiment in which the binding capacity of 
small HBsAg, large HBsAg and synthetic preSl was investigated. As is the case for 
native human Ell, large HBsAg also is capable of efficient binding to recombinant Ell 
(lanes 2, duplicate experiments). There is a negligible binding to synthetic preSl peptide 
(lanes 3) and no binding at all to BS A (lanes 4). Figure 9 shows the complexes that are 
formed when radiolabelled recombinant Ell is crosslinked to small HBsAg (lane 2). A 
protein complex with an apparent molecular weight of 85 kD is formed. This protein 
complex might be the result of one Ell molecule (34 kD) and two HBsAg molecules 
(2x26 kD) or two molecules of Ell with one molecule of HBsAg. 
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Discussion 
In previous work we have demonstrated that human EH is involved in the Ca+^depen­
dent binding of HBsAg to the human liver cell (6, 11, 12). Ell is a member of the family 
of annexins, a group of highly conserved proteins with Ca2+-dependent phospholipid 
binding properties. The function of these proteins is not clear. It has been suggested that 
they may be involved in endocytosis and exocytosis by promoting membrane fusion (9, 2 
, 13). In rabbits immunized with purified human liver Ell not only anti-EII, but also anti-
idiotypic antibodies, reacting with HBsAg, appeared (7). Since the Ell preparation, used 
to immunize this rabbit, was proved not to be contaminated with HBsAg, the appearance 
of anti-idiotypic anti-HBsAg antibodies can only be explained by a ligand-receptor 
relationship of Ell and HBsAg. 
Despite the large amount of evidence that is available now that Ell serves as a binding 
protein for HBsAg, its biological role is not clear yet, e.g. the question remains to be 
answered whether Ell also serves a role as a receptor for the complete hepatitis В virus 
particle, thus permitting viral penetration into the liver cell, the initial step of infection. 
Because of its HBsAg binding properties, EH can be considered to be a very serious 
candidate as a HBV receptor. Experiments have to be done to definitely prove the 
biological role of EH in HBV infection, and to understand the whole cascade of virus 
entry into the liver cell. If it is indeed possible to prove the HBV-receptor function of 
Ell, then this research will have a lot of potential implications for vaccine development 
and even for therapy of chronic hepatitis В patients. When it is possible to block the 
interaction between virus and liver cell, the continuing re-infection of the liver in these 
patients might be stopped, leading to recovery. 
To conduct research to the mechanism of virus entry, large amounts of functionally active 
receptor protein are required. To meet this goal, we chose to clone the EH cDNA in the 
well defined baculovirus expression system. This system is nowadays widely used for the 
high-yield production of all kinds of eucaryotic proteins (4, 10, 15). 
The recombinant protein that is produced in this system has the same molecular weight 
and iso-electric point as the native protein. Moreover, it behaves identical as the native 
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protein in regard to HBsAg- and phospholipid binding, as it can be isolated using a 
protocol for the isolation of native Ell, based on Ca2+-dependent phospholipid binding 
properties. When crosslinking studies are performed with small HBsAg and Ell, com­
plexes are found with molecular weights that indicate the presence of two binding sites on 
Ell for HBsAg, or two binding sites on HBsAg for Ell. 
The availability of large amounts of recombinant Ell, functionally active in regard to 
HBsAg binding, may therefore be of considerable importance in future hepatitis В 
research. 
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CHAPTER 5 
Summary 
To investigate the possible existence of a reactive binding site(s) on the hepatitis В surface 
antigen (HBsAg) for the hepatitis delta antigen (H5Ag) in the hepatitis delta virus (HÔV), 
we performed binding studies using recombinant (rec)Small-, recMiddle-, recLarge 
HBsAg and recombinant small(S)- and large(L) hepatitis delta antigen (recSôAg, 
recLöAg). 
RecSAg was immobilized onto microtiter plates and incubated with recSmall-, recMiddle-
and recLarge HBsAg. Of the three HBsAg proteins only the recMiddle HBsAg was found 
to bind to recSSAg. This binding was inhibited by the addition of synthetic PreS2 peptide 
but not by small HBsAg, indicating that the SSAg exhibits a PreS2 binding site. RecLMg 
bound to all three forms of HBsAg. The binding of radio-labelled HBsAg to recLôAg was 
saturable and could be blocked with an excess of unlabelled HBsAg, but not with BSA. 
Therefore the region of the additional 19 amino acids of the LSAg is responsible for the 
creation of the small HBsAg binding site on the L5Ag. We suggest that all HBsAg 
proteins but particularly the small HBsAg in the HSV coat seems to be involved in the 
interaction with the H6V core particle. 
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Introduction 
The hepatitis delta virus (HôV) is a subviral agent. Infection with Ηδν can only occur as 
a coinfection with hepatitis В virus (HBV) or as a superinfection of HBV carriers (22, 23, 
24). The Ηδν virion consists of a 36 nm hepatitis В surface antigen (HBsAg) coated 
particle containing the HÔV-specific delta antigen (HÔAg) and the 1.7kb circular single 
stranded HÔV RNA genome (14, 16, 29). The HÔAg is the only known HÔV RNA related 
protein and occurs in two forms: a 24kD small HÔAg (SôAg) and a 27kD large HÔAg 
(LôAg)(l, 16, 25). The LôAg is expressed as a result of sequence heterogeneity in the 
HSV RNA (5, 19, 33) and contains an additional 19 amino acids (aa) at the amino 
terminus of 195 aa SÔAg. Both HôAgs are nuclear-proteins with a strong RNA binding 
capacity (3, 18). Although the precise biological role of both forms of HÔAg is not yet 
understood, it has been suggested that SôAg is important for the initial steps of HÔV RNA 
replication, regulation of the HÔV infection and for transport of the Ηδν RNA to the 
nucleus of the host cell. (6, 12, 16, 19, 32), while the LôAg plays an essential role in 
Ηδν particle formation (26, 30, 4, 8). 
The HBsAg protein is composed of three molecular forms: small-, middle- and large 
protein. The small protein of the HBsAg is encoded by the S gene, the middle protein by 
the S gene and the PreS2 region and the large protein is encoded by the S gene, the PreS2 
region and the PreSl region of the HBV genome (9, 20, 28). 
The HBsAg envelope of Ηδν has a similar polypeptide composition as the HBsAg 22 nm 
particles found in serum of HBV infected patients: predominantly small HBsAg, 5-10% 
middle HBsAg and virtually no or less than 1% large HBsAg (1, 27). 
In this paper we report that recombinant (ree) SôAg only shows a specific binding to 
recMiddle HBsAg. PreS2 peptide is found to inhibit this binding specifically. We 
therefore suggest that the PreS2 region may play a role in the binding of SÔAg to HBsAg 
during HôV particle formation. RecLôAg however showed a specific interaction with all 
three HBsAg proteins, indicating that the additional 19 aa of the LôAg are responsible for 
the creation of the small HBsAg binding site(s) on the LôAg. 
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Materials and methods 
Production and isolation of recS5Ag 
RecSôAg was produced in Spodoptera frugiperda (Sf9) cells using the baculovirus 
expression system. SÍ9 cells were cultured in TC100 medium (Life technologies, 
Gaithersburg, Md, USA) supplemented with 10% heat inactivated foetal calf serum (FCS, 
Flow laboratories, McLean, Virginia, USA) and 40 μg/ml gentamycin (Schering 
corporation Kenilworth, New Jersey, USA) at 27 "C without C0 2. Sf9 cells (20xl06) were 
infected with Acôl, a baculovirus containing HÔV-cDNA encoding the entire small H5Ag 
gene (15), with a multiplicity of infection of 10. 72 hrs after infection cells were lysed in 
ice cold lysis-buffer (150 mM NaCl, 50 Mm Tris.Hcl Ph 8.0, 0.5% Nonidet P-40) kept 
on ice for 5 minutes and vortexed vigorously 3 times. The nuclei, containing the 
recSSAg, were pelleted by centrifugation for 5 minutes at 300 g. The nuclei were washed 
with phosphate buffered saline (PBS) and resuspended in 100 μ\ digestion buffer (2 Mm 
CaCl2, 2 mM MgCl2, 20 mM Tris.HCl pH 8.0, 100 mM NaCl, 5 ng DNAse and RNAse 
(Boehringer, Mannheim, Germany) and 0.1 mM protease inhibitor phenylmethylsul-
fonylfluoride (PMSF, Sigma Chemie, Brussels, Belgium)). The nuclear-suspension was 
incubated for 10 minutes on ice and 10 minutes at room temperature. NaCl was added to 
a final concentration of 2 M and the suspension was centrifugated for 15 minutes at 
12,000 g to remove debris. The supernatant, containing the recSôAg, was extensively 
dialysed against PBS and stored at 4 °C until use. 
Purification of recSMg 
The crude recSÔAg, isolated as described above, was diluted with one volume non-
reducing Polyacrylamide gel electrophoresis (PAGE) sample buffer (0.1% SDS, 20% 
glycerol and broomphenol blue) and electrophoresed on a 10% SDS Polyacrylamide gel. 
The recS5Ag was cut from the gel and electro-eluted using a Biotrap apparatus 
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(Schleicher & Schüell, Dassel, Germany). The protein was dialysed extensively against 
PBS. Protein concentration was determined using a protein assay kit (Biorad, Richmond, 
CA, USA). 
The recLiAg and recHBsAg 
The recLMg was produced in E.coli as described elsewhere (2) and was kindly provided 
by Dr. F. Bonelli (Sorin Biomedica, Diagnostic division, 13040 Sallugia, Italy). 
The recSmall-, recMiddle- and recLarge HBsAg were kindly provided by Dr. Miller 
(Merck Sharp & Dohme, Research Laboratories Westpoint, PA, USA). The production 
and purification of the yeast derived HBsAg are described elsewhere (11). 
Solid-phase binding assay between recH6Ag and recSmall- or recMiddle HBsAg 
Microliter plates (Greiner labortechnik, Nürtingen, Germany) were coated with 500 ng 
recSSAg, recOAg or bovine serum albumin (BSA, Boehringer, Mannheim, Germany) as 
a control in 50 μ\ PBS per well by overnight incubation at 4 °C. The dishes were washed 
5 times with PBS/0.05 % Tween and non-specific binding was blocked by incubation with 
3% gelatin in PBS for 2 hrs at room temperature (RT). The coated wells were incubated 
for 2 hrs at RT with recSmall- or recMiddle HBsAg in PBS with 2 mM CaCyMgCl2. 
After 2 hrs of incubation non-bound HBsAg was removed and the wells were washed 
three times with PBS/0.05% Tween. Bound recSmall- and recMiddle HBsAg were 
detected by a 2 hr incubation with 1:800 diluted goat-anti-HBsAg (DakoPatts, Glostrup, 
Denmark), followed by a 1 hr incubation with 1:800 diluted horseradish peroxidase 
conjugated rabbit-anti-goat (Nordic, Tilburg, The Netherlands). After colour development 
with 5-aminosalicylic acid (5-ASA), absorbance at 450 nm was determined in a automated 
ELISA plate reader. 
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Solid-phase binding assay between recH£Ag and radiolabelled recLarge HBsAg 
To study the binding of the recLarge HBsAg to recHôAg, a solid phase binding assay was 
performed using radiolabelled recLarge HBsAg (recLarge HBsAg is also kindly provided 
by Dr. Miller, Merck Sharp & Dohme, Research Laboratories Westpoint, PA, USA). 
RecLarge HBsAg was radiolabelled with I25I as described previously (17). The specific 
activity was 1.9xl07 cpm/ug HBsAg. 
500 ng recSSAg, recLMg or BSA were coated per well and incubated with approximately 
100,000 counts per minute (cpm) ,MI-recLarge HBsAg for 2 hrs in PBS in the presence of 
2 mM CaCl2/MgCl2. After 2 hrs of incubation non-bound 125I-recLarge was removed and 
the wells were washed 3 times with PBS/Ca/Mg. Bound 125I-recLarge was removed from 
the wells using PAGE sample buffer and radioactivity was determined in a gamma-
counter (LKB, Pharmacia, Upsala, Sweden). 
Results 
RecSÔAg was produced in Sf9 cells using the baculovims Ac51, containing the Ш -
cDNA encoding the entire small HÔAg (15). 72 hrs after infection the nuclei of Ac61 
infected cells, containing the recSSAg, were harvested. The recSôAg constitute more than 
50% of total nuclear protein (figure 1A) and has a molecular weight of 24Ш. From this 
crude preparation, recSÔAg was purified by preparative gel electrophoresis. The recSÔAg 
preparations contained no detectable contaminating proteins (figure IB) and reacted with 
anti-HôAg polyclonal antibodies derived from chimpanzee serum (Biomedical Primate 
Research Centre TNO, Rijswijk, The Netherlands) showing the immuno-specificity of the 
recSôAg (figure 1С). The recSÔAg was also able to bind H5V RNA in a RNA-binding 
assay as described by Chang et al. (3, results not shown). Based on this information we 
concluded that the recSÔAg has the same properties in respect to its size, immuno-
specifity and RNA-binding capacity as the native S5Ag. The same applies for the 
immuno-specificity and the RNA-binding capacity of the recLMg (2). 
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Figure 1. A). SDS-PAGE size separated nuclear fraction of АсЫ infected Sf9 cells (Lane 1, crude 
recSbAg preparation) and non-infected Sf9 cells (Lane 2) stained with Coomassie 
brilliant blue (CBB). Molecular weight markers are indicated (M). The arrowhead 
indicates recSòAg. In figure IB the purified recSbAg did not contain any contaminating 
proteins on PAGE stained with CBB. On immunoblot (figure 1С) the recSbAg reacted 
specifically with chimpanzee polyclonal anti-HòAg. 
In order to study the binding of H5Ag to HBsAg, microtiter plates coated with recSôAg, 
recLSAg or BSA as a control were incubated with recSmall- or recMiddle HBsAg respec-
tively. The binding of the HBsAg to the immobilized protein was detected using specific 
antibodies to small HBsAg. As shown in figure 2 only recMiddle HBsAg was found to 
bind specifically to the recSSAg. No detectable binding of recSmall HBsAg to rec-
SôAg under these experimental conditions was found. For determination of the binding 
site(s) of the recMiddle HBsAg for recSôAg, we performed inhibition studies with rec-
Middle HBsAg and synthetic PreS2 peptide (Organon Teknika, Boxtel, The Netherlands) 
or recSmall HBsAg. The presence of 5- or 10-fold molar excess of recSmall HBsAg has 
no effect on the binding of recMiddle HBsAg to recSôAg (figure 3). This finding is com-
patible with the observation that recSmall HBsAg does not react with recSôAg. 
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Figure 2. Binding of recSmall- and recMiddle HBsAg to recSòAg, SDS treated recLbAg, 
recLbAg and BSA in PBS/2mM Ca2*/Mg2*. Detection of bound HBsAg was 
determined by ELISA. Binding is expressed as the absorption at 450 nm. 
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Figure 3. Influence of five and ten fold molar excess of recSmall protein and synthetic 
PreS2 peptide (Organon Teknika, Boxtel, The Netherlands) on the binding of 
recMiddle HBsAg to recSbAg. Inhibition is expressed as percentage of the total 
binding. 
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However when 5- and 10-fold molar excess of PreS2 is present in the experiments, the 
binding of recMiddle HBsAg was reduced with 34% and 82.5% respectively (figure 3). 
The recLôAg showed different binding properties as compared to the recSôAg. RecLôAg 
was able to bind to both the recSmall and the recMiddle HBsAg. This was also seen when 
SDS denaturated recLMg was used, indicating that the binding sites on the recLSAg for 
the small HBsAg sequences as well as on the recSSAg for the PreS2 sequences are not 
conformational epitopes. 
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Figure 4. Binding of radiolabelled recharge HBsAg to recSòAg (1), BSA (2) 
and rech&Ag (3). The amount of bound radiolabelled recharge 
HBsAg is expressed in counts per minute (cpmj. The binding of 
recharge HBsAg to rechhAg can be blocked by the addition of 
excess recSmall HBsAg (4). 
The binding of the recLarge HBsAg to the recôAg proteins was investigated by a binding 
assay with radiolabelled recLarge HBsAg. As shown in figure 4 there is no specific 
binding between the recS5Ag and recLarge HBsAg, while recLoAg showed a specific 
binding to radiolabelled recLarge HBsAg. Excess recSmall- or recMiddle HBsAg (result 
not shown) were able to inhibit this binding, suggesting that the interaction again takes 
place via the small HBsAg sequences. 
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Figure 5. Specific binding of radiolabelled HBsAg to L6Ag in a solid phase 
binding assay. The amount of bound HBsAg is expressed in cpm. 
The binding of HBsAg is not inhibited by presence of excess BSA. 
in order to investigate if the solid phase binding assay as described above, is a reliable 
method, a dose response curve was determined. Wells coated with recL5Ag were 
incubated with increasing amounts of radiolabelled HBsAg. Aspecific binding was determ­
ined by incubation in the presence of 10 molar excess of unlabelled HBsAg. As shown in 
figure 5 the binding of HBsAg to L5Ag is saturable. In addition does excess BSA not 
affect this binding (result not shown), indicating the specificity of the binding property. 
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Discussion 
ГО was initially classified as a subviral agent. For its propagation it depends on the 
presence of HBV (22). However, transfection of HSV cDNA alone into a human 
hepatoma cell line resulted in active replication of the HSV genome (7, 16). Subsequent 
analysis showed that this cell line does not produce HSV or HSV like particles. HSV 
virions can only be recovered after co-transfection with HBV DNA (31). These findings 
suggest that HBV is indispensable for the formation of the HSV virion at least by 
providing the proteins that constitute the virion envelope. By means of cotransfecting cells 
with various HSV and HBV constructs several features about assembly of the HSAg and 
HSV RNA into particles became clear: 1) The small HBsAg is sufficient for packaging of 
the HSV. 2) The LSAg is required for the assembly of such particles. 3) Prenylation of 
LSAg at the prenylation site on the last four amino acids of the LSAg, is indispensable for 
HSV particle formation (13). 4) The SSAg can only be packaged in the presence of LSAg 
(8, 26,30). But the exact mechanism of HSV particle formation has not yet been 
unravelled. 
In the present study, we demonstrate that LSAg displays a specific binding affinity to all 
three forms of HBsAg via a binding site located on the small HBsAg sequences. In 
contrast the SSAg does not bind to small HBsAg. This finding indicates that the additional 
19 amino acids of the LSAg somehow create the small HBsAg binding site. These results 
are consistent with the findings of Ryu et al. (26), showing that the LSAg is required for 
the assembly of HSV particles and that the small HBsAg is sufficient for the packaging of 
the HSV. The fact that SSAg can not be packaged in absence of LSAg may be explained 
by the lack of binding properties of SSAg to the small HBsAg. However through its 
binding to PreS2 sequences, it may also be packaged by binding to middle HBsAg when 
particles are formed in the presence of large delta antigen. 
In the present study the recSSAg was isolated under SDS denaturating conditions. In order 
to examine whether this condition does affect the binding properties of the recSSAg, we 
also performed binding studies with SDS denaturated recLSAg. SDS treatment did not 
change the binding capacity of the recLSAg. The binding epitopes for the HBsAg proteins 
are not disrupted by the presence of the SDS, indicating that the reactive binding sites for 
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the HBsAg sequences are not conformational. 
The recLMg used in the experiments is not prenylated. Since Glenn et al. (13) showed 
that prenylation of L¿Ag at its carboxy-terminus is essential for the formation of HSV 
particles. RecLMg, despite the absence of prenylation, was able to bind to the recSmall 
HBsAg, therefore it is very likely that prenylation is not responsible for the creation of 
the reactive binding site for small HBsAg on the L5Ag. 
In contrast to the binding of middle HBsAg to the small delta antigen, binding of radio-
labelled recLarge HBsAg containing the PreS2 sequence to recSôAg was not demonstra-
ted. The absence of the interaction between the recSSAg and the recLarge HBsAg is 
probably due to steric hindrance by the presence of the PreSl sequences. RecLMg, 
however binds specifically to recLarge HBsAg. This binding could be inhibited by the 
recSmall- and recMiddle HBsAg. From these experiments we can therefore conclude, that 
both the small HBsAg and PreS2 sequences are involved in the interaction between the 
HBV surface proteins and the delta antigens. The reactive binding sites on the LMg for 
the small HBsAg and on the SSAg for the PreS2 sequences may play a crucial role in the 
interaction of the Ш core-particles and the hepadna virus envelope proteins and 
therefore probably for the formation of Ш particles. 
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CHAPTER б 
Summary 
Recently we identified human liver endonexin II (£11) as a specific hepatitis В surface 
antigen (HBsAg) binding protein. To investigate whether Ell is also able to interact with 
the HBsAg of hepatitis delta virus (HÔV), immunoprecipitation experiments were perfor-
med. HSV particles could be precipitated by polyclonal rabbit anti-EII, but not by rabbit 
anti-gluthation S transferase τ (GSTT) antibodies from an Ш enriched fraction 
containing ΕΠ and GSTx. These findings suggest that H6V particles were co-precipitated 
by anti-EII as an consequence of the binding between HBsAg present in the HÔV 
envelope and Ell. Furthermore, binding of HôV particles to human hepatocytes could be 
inhibited by incubation of the liver cells with rabbit anti-EII IgG's or the HôV particles 
with anti-idiotypic (anti-HBsAg) IgG's. These findings support the assumption that small 
HBsAg present in the ΗδΥ envelope plays an important role in this process. 
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Introduction 
Hepatitis delta virus (Ш ) is a subviral agent, which replicates as a satellite of hepatitis 
В virus (HBV). The envelope of HÔV consists of hepatitis В surface antigen (HBsAg) 
provided by HBV (26, 27). HBsAg occurs in three molecular forms: small- middle- and 
large HBsAg with identical C-terminal regions. The small HBsAg is encoded by the S 
gene, the middle HBsAg by the S en PreS2 region and the large HBsAg by the S, PreS2 
and PreSl regions of the HBV DNA (8, 31). The envelope of H5V has a similar 
polypeptide composition as the 22 nm HBsAg particles found in serum of HBV infected 
patients. It consists of predominantly small HBsAg , 5-10% middle HBsAg and no or less 
than 1% large HBsAg (1). 
For enveloped viruses such as HBV and HÔV it has been generally accepted, that a 
specific interaction between the envelope component(s) and cell membrane domain(s) on 
susceptible host cells is the essential initial step of infection. This binding leads to 
initiation of penetration into the cytoplasm by endocytosis or membrane fusion (19). For 
HBV and Ш such receptor has not yet been identified so far. Since the envelope of both 
viruses are composed of the same components, it is likely that these viruses make use of 
the same receptor molecule for entry into the host cells. Recently we have identified 
endonexin II (Ell), present on human liver plasma membranes, as a specific HBsAg 
binding protein (11). Although demonstration that this protein is directly involved in 
HBV infection is still in progress, we have already shown that the binding of small 
HBsAg to human hepatocytes is specific and can be inhibited by native or recombinant 
human Ell and by anti-idiotypic antibodies. These antibodies, which react with HBsAg, 
occurred spontaneously in rabbits immunized with Ell (12). 
In the present study we demonstrate that Ell is able to bind to HÔV particle, via a specific 
interaction with the HBsAg component of the HSV coat and that H5V particles bind 
specifically to human hepatocytes. This binding could be specifically inhibited by incu-
bation of the liver cells with anti-EII or HSV particles with anti-idiotypic (anti-HBsAg) 
antibodies. These findings strongly suggest that Ш and HBV may indeed use the same 
receptor for attachment to human liver cells as initial step in their infection cycle. 
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Materials and methods 
Recombinant large hepatitis delta antigen (recLMg), HBsAg and Ell 
RecLSAg (E.coli derived) was kindly provided by Dr. F. Bonelli ( Sorin Biomedica, 
Diagnostic Division, 13040 Saluggia, Italy). The production and purification of this 
protein has been described elsewhere (3). 
The recombinant small, middle and large HBsAg (yeast derived) were a kind gift of Dr. 
Miller (Merck Sharp & Dohme, Research laboratories WestPoint, PA, USA,(10)). 
The production, isolation and purification of recombinant Eli (recEII) in Spodoptera 
frugiperda (Sf9) cells using the baculovirus expression vector Acendo-1.4AE will be 
described elsewhere (20). 5μg recEII was radio-labelled with Nal125 (Amersham, Buckin­
ghamshire, UK) using the Iodogen (l,3,4,6-tetracloro-3a-6ot-diphenylglycoluril, Pierce, 
Rockford, IL, USA) method according to manufacturers instructions. 
Solid phase binding assay with radio-labelled recEII 
Microtiter plates (Greiner labortechnik, Nürtingen, Germany) were coated with 500 ng 
recLÖAg or bovine serum albumin (BSA, Boerhinger, Mannheim, Germany) as a control 
protein in 50 μΐ phosphate buffered saline (PBS) per well by overnight incubation at 4°C. 
The dishes were washed 5 times with PBS/0.05% Tween and aspecific binding sites were 
blocked by incubation for 1 hr at room temperature (RT) with 3% gelatine in PBS. The 
wells were washed with 3 charges of PBS/0.05% Tween and 2 times with PBS. The wells 
were then incubated for 2 hrs with the 3 different recHBsAg proteins in PBS containing 2 
mM CaCl2/MgCl2 (PBS/Ca/Mg). After 2 hrs non-bound recHBsAg was removed by 
washing 3 times with PBS/Ca/Mg. The wells were then incubated for 2 hrs with 
approximately 100.000 cpm radio-labelled recEII in PBS/Ca/Mg at RT. After 2 hrs the 
wells were washed with 3 charges of PBS/Ca/Mg to remove the unbound recEII. The 
bound proteins were recovered from the dishes by incubating them for at least 30 minutes 
with Polyacrylamide gel electrophorese (PAGE) sample buffer (0.1% SDS, 20% glycerol, 
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5 mM dithiotreithol (OTT) and broomphenolblue). The radioactivity was determined in a 
gammacounter (LKB, Pharmacia, Upsala, Sweden). 
Precipitation of H5V particles and dotblot hybridization with a H5Ag specific cDNA 
probe 
Chimpanzee serum containing HSV (Biomedical Primate Research Centre, TNO, 
Rijswijk, The Netherlands) was diluted 5 times with PBS, layered on a 20% sucrose 
cushion and centrifuged for 4 hrs at 120.000 g at 4 °C. The pellet containing the HôV 
particles was resuspended in PBS/Ca/Mg and incubated for 2 hrs at RT with recEII or 
with glutathione-S-transferase τ (GSTx) as a control protein. After 2 hrs rabbit anti-EII 
(12) or rabbit anti-human GSTx (GST and anti-GSTT were kindly provided by Dr. Peters 
(22), were added to a final dilution of 1:5 or 1:500 and incubated for an additional 2 hrs 
at 4 °C. The immunoprecipitate was collected by centrifugation for 20 minutes at 12.000 
g and washed 3 times with PBS/Ca/Mg and resuspended in the incubation-buffer. Vanadyl 
ribonucleoside complex (VRC, Life technologies, Gaithersburg, Md, USA) was added to 
a final concentration of 1 mM to inhibit RNAse activity. 20xSSC (final concentration 
6xSSC) and 0.1 volume 37% formaldehyde were supplemented to the immunoprecipitate. 
After incubation for 15 minutes at 60 °C the solution was spotted on Hybound-N 
membrane (Amersham, Buckinghamshire, UK) and the membrane was baked for 2 hrs at 
80 °C. The blot was hybridized overnight at 65 °C with the 32P-labelled delta specific 
probe pGEMÔ17.3 (15) to detect the presence of HSV RNA. The filters were washed and 
subjected to autoradiography. 
Hepatocyte isolation 
Human liver tissue was obtained from post-mortem organ donors under approvement of 
the local committee for human experimentations and informed content of the family. Rat 
liver tissue was obtained via the Central Laboratory Animal Research (University of 
Nijmegen, The Netherlands). The hepatocytes were isolated from these tissues by a two 
step collagenase perfusion, according to the method of Rijntjes et al. (25). The hepatocy-
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tes were cryopreserved, stored and thawed as described previously (18). 
Binding of HSV particles to human hepatocytes 
Hepatocytes were suspended in William's E medium (WEM) containing 0.5% BS A and 
incubated for 1 hr at 4 "C to block the non-specific binding. This was followed by an 1 hr 
incubation with 10% non-immune serum IgG's (0.14 mg/ml). 500.000 cells were 
incubated with HSV particle enriched fraction for 2 hrs at 4 'C in PBS/Ca/Mg. The cells 
were subsequently washed 3 times with ice-cold PBS/Ca/Mg and the presence of HSV 
RNA was detected using dotblot hybridization as described above for the precipitation 
experiments. 
In parallel experiments the cells were incubated with 10% anti-EII IgG's (0.05 mg/ml) or 
the HSV enriched fraction was preincubated with 1% anti-idiotypic (anti-HBsAg) IgG's 
(0.08 mg/ml). These experiments were performed to investigate whether the attachment 
of HÖV to human hepatocytes takes place by an interaction of HBsAg of the HSV coat 
and ΕΠ. Incubation of rat hepatocytes with HSV particles served as negative control. 
Results 
To examine whether HSV particles are able to bind efficiently to the Eli, a specific 
HBsAg binding protein, HSV particles enriched fraction from chimpanzee serum were 
incubated with recombinant Ell (recEII) or glutathione-S-transferase τ (GSTT) as a 
control protein. These proteins were subsequently immunoprecipitated with rabbit 
polyclonal antibodies against respectively recEII or G S T T . These antibodies did not show 
any cross-reactivity and the affinity for their respective antigens were comparable (data 
not shown). The immunoprecipitates were examined for the presence of HSV RNA by dot 
blot hybridization with a 32P-labelled HSAg specific cDNA probe. As shown in figure 1 
HSV RNA was demonstrable in the recEII and anti-EII complex, while it was absent in 
the G S T T and anti-GSTT complex. These findings suggest that HSV particles are co-
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precipitated by the immune-precipitation of Ell and not with GSTx. 
Figure 1. Autoradiogram of dotblot hybridization assays of immunoprecipita-
tion using a "P-labelled H6V cDNA probe. Immunoprecipilation of 
HhV particles from a HhV enriched fractions was performed using 
antibodies against (Bl +2) or human gluthatione-S-transferase ж 
(B3 + 4) in the presence of their respective antigens. HbV cDNA 
(Al) and Ш particles enriched fraction (C) was used as control 
for the hybridization. 
Previously we have demonstrated that recOAg was able to bind specifically to all three 
molecular forms of the HBsAg, while the small form of the HôAg only bound to middle 
HBsAg. The binding of large HBsAg to recLôAg was inhibited by small- and middle 
HBsAg (2). The specific interaction between large HôAg and small HBsAg is consistent 
with the essential role of these two proteins in the HôV particle formation (29, 32). 
In order to investigate if the co-precipitation of H5V particles with Ell and its corres-
ponding antibody, takes place via a specific binding of Ell to the HBsAg component of 
the H5V particles, binding studies with recL5Ag, recHBsAg and recEII were performed. 
RecLôAg or BSA were immobilized onto microtiter plates and incubated with recSmall-, 
recMiddle- and recLarge HBsAg or gelatin as control protein and subsequently with 
recEII. 
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Figure 2. Binding of radio-labelled recombinant EH to recombinant LbAg or 
BSA coated microliter dishes in presence of recombinant small-, 
middle- or large HBsAg or gelatine in PBS/Ca/Mg. 
As shown in figure 2 both recLôAg and BSA were not able to bind to recEII directly. 
However, when recLôAg was first incubated with recHBsAg, recEII was found to bind 
specifically to recLSAg coated plates. In contrast recEII did not bind to BSA coated 
plates, even when incubated with recHBsAg. These findings suggest that Ηδν particles in 
the first experiment were co-precipitated by the anti-EII as the consequence of binding 
between HBsAg present in the Ηδν envelope and Ell. 
To demonstrate that native Ηδν particles were indeed able to bind to human hepatocytes 
via a specific interaction between HBsAg of the Ηδν coat and Ell on the surface of 
human hepatocytes, binding experiments with human liver cells and native Ηδν particles 
were also performed. Human hepatocytes were incubated with Ηδν particles enriched 
fraction from chimpanzee serum for 2 hrs at 4 °C. After washing the cells 3 times with 
PBS/Ca/Mg, the binding of HSV particles to human hepatocytes was determined by the 
presence of HSV RNA in the cell pellet by dotblot hybridization. In figure 3 the results of 
these experiments are shown. Incubation of the hepatocytes with anti-EII IgG's 
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Figure 3. Autoradiogram ofdotblot hybridization assays of the binding of HhV 
particles to human hepatocytes. Human hepatocytes were incubated 
with rabbit non-immune serum IgG's (Al+2) or rabbit anti-Ell 
IgG's (A3+4) prior to the incubation with НЬ particles or the HbV 
particles were preincubated with rabbit anti-idiotypic IgG's (Bl+2) 
before admission to the liver cells. HÒVparticles did not bind to rat 
hepatocytes (B3 + 4). 
or the H5V particles with anti-idiotypic anti-HBsAg IgG', both inhibited the binding of 
HôV particles to the human hepatocytes specifically. Rat hepatocytes didn't bind Ηδν 
particles under the same experimental conditions. These results strongly suggest, that 
Ηδν is able to attach to human hepatocytes by a specific interaction between HBsAg of 
the Ηδν coat and Ell on the plasma membrane of the cells. 
Discussion 
Although binding domains located on the surface of the hepatitis В virion possibly 
mediating host- and tissue specific recognition have been studied intensively in the last 
decade, a receptor molecule on the human hepatocyte membrane for the HBV infection 
111 
CHAPTER б 
has not been identified so far. Several studies have suggested that the PreS2 domain on 
the HBV virion via monomelic or polymerized human serum albumin (pHSA) could act 
as a site for attachment on the hepatocyte for the virion (17), but other observations 
suggested that the PreSl domain is the most important for attachment on human liver cell 
membrane. (21, 23). Furthermore, a specific protein on human liver cells responsible for 
binding to the PreSl and PreS2 domain of the HBV envelope has not been discovered so 
far. Recently we have identified human endonexin II (Ell) present on human liver cell 
membranes as a specific small HBsAg binding protein (11). EH is a member of the family 
of Ca2+ dependent phospholipid- binding proteins known as the annexins (9, 13). 
Although demonstration that Ell directly is involved in the initial steps of a HBV infection 
is still in progress, evidences are accumulating that suggest the presence of an unique and 
specific initial interaction between human endonexin II and small HBsAg. Previous 
studies on H5V infection in vitro have shown that anti-S antibodies preclude H5V 
infection (30). By means of co-transfection of cells with various H5V cDNA and HBV 
DNA constructs (29, 30, 32) it was also demonstrated, that small HBsAg is sufficient for 
assembly of H5V particles. These particles are infectious in vitro, although particles 
containing all three molecular forms of HBsAg show increased infectivity (29). These 
findings are consistent with the assumption that H5V makes use of small HBsAg present 
on the HôV surface for attachment and penetration into human hepatocytes. In a previous 
study (2), we have demonstrated that small HBsAg has an unique binding site for large 
H6Ag, while small HSAg binds specifically to middle HBsAg via a binding domain in the 
PreS2 sequences. In this study, we show that LÔAg is not able to interact directly with 
Ell, a specific HBsAg binding protein (11). However H5V particles, incubated with Ell, 
are precipitable by antibodies against Ell. Furthermore, we demonstrated that L£Ag 
incubated with HBsAg is able to attach to Ell and native H5V particles are able to bind 
specifically to human hepatocytes via this human liver protein. These findings indicate 
that H5V particles are able to bind to Ell on the plasma membrane of human hepatocytes 
via small HBsAg present in the Ш envelope and support the assumption that small 
HBsAg plays an important role in the initiation of the H5V infection. However, further 
studies, that demonstrate that Ell is involved in HôV infection, remain required. 
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Summary and conclusions 
The majority of clinical hepatitis is caused by an infection with one of the known hepatitis 
viruses (HAV-HEV). Two of them, hepatitis В virus (HBV) and hepatitis delta virus (H5V) 
are highly related. The coat of these viruses are both constituted of three hepatitis В surface 
proteins: small-, middle- and large HBsAg. The relative proportion in which these proteins 
are present in the coat is however different for both viruses. H6V depends on the presence 
of HBV for completion of its own infection cycle. 
HBV displays a strong species and tissue tropism. It only infects humans and some non-
human primates, like chimpanzee and gibbon, and predominantly replicates in the livers of 
these species. A possible explanation for this phenomenon could be the presence of a specific 
receptor on the hepatocytes of the susceptible hosts, interacting with viral envelope proteins. 
Endonexin II, isolated from human liver tissue was identified as a specific HBsAg binding 
protein. The research described in this thesis is therefore directed to HBsAg and HBsAg 
binding protein endonexin II. 
After immunization of rabbits with human liver endonexin II not only anti-human endonexin 
II antibodies, but also anti-idiotypic antibodies were generated. The anti-anti-endonexin II 
antibodies react with HBsAg, indicating that a receptor-ligand relationship between endonexin 
II and HBsAg must exist. In chapter 2 HBsAg was conjugated to 10 nm collodiol gold to 
study the binding and internalization of HBsAg by human hepatocytes. For this purpose 
human hepatocytes were incubated with HBsAg-gold at 4°C. Warming of the cells to 37°C 
resulted in direct invagination of the coated pit region at which the HBsAg was bound. 
Incubation of the hepatocytes with anti-endonexin II or HBsAg with anti-idiotypic (anti-
HBsAg) antibodies both inhibited the binding of HBsAg-gold to the human hepatocytes 
specifically. These results strongly suggest that human liver endonexin II is involved in the 
specific binding and subsequent internalization of HBsAg and might act as HBV receptor. 
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As mentioned before, HBV displays a strong species and tissue tropism. In chapter 3 the 
relationship between the presence of HBsAg binding protein endonexin II and the species 
specificity of HBV is demonstrated. Using immunoblotting, endonexin II was only detectable 
in liver tissues of species, which are susceptible for a HBV infection and plasma membrane 
fractions of these tissue were able to bind HBsAg specifically. These results indicate that the 
presence of endonexin II is correlated with the host range of HBV. The expression of 
endonexin II however, was not restricted to the liver, but was also demonstrated in other 
human tissues. The hepatotropism of HBV seems therefore not to be related to the tissue 
specific expression of endonexin II. The extra-hepatic expression of endonexin II can 
however explain the detection of HBsAg and HBV DNA in non-hepatic tissues. Although 
HBV replicates in some of these tissues, the liver is the major site of viral replication. The 
most favourable explanation for the hepatotropism of HBV is, that HBV depends on the 
presence of some liver specific factors, which regulate the transcription of the HBV DNA. 
In chapter 4 endonexin II cDNA was isolated from a human cDNA library, using oligonucl­
eotides synthesized according to placental endonexin II cDNA sequences. The endonexin II 
cDNA was cloned in the baculovirus expression system. Resulting recombinant endonexin 
II has the same molecular weight, isoelectric point and HBsAg binding properties as the 
native protein. It is also very easy to purify this recombinant endonexin Π according to 
methods, earlier described for native endonexin II from placenta. Although different 
functions of endonexin II have been postulated (section 1.1.7), its precise biological role has 
not been identified so far. Because the recombinant protein seems to have the same properties 
as native endonexin II, it may become an important tool, not only in HBV research, but also 
in resolving the biological function of this protein. Recombinant endonexin II is used in the 
experiments described in chapter 6. 
The HSV particle is constituted of a core of hepatitis delta antigen (HSAg) and the H3V RNA 
molecule, packaged in an envelope of HBsAg. Somehow during the H5V life cycle these 
particles must be formed. In chapter 5 the existence of a possible reactive binding site(s) on 
small HSAg (S¿Ag) and large HôAg (LMg) for the three HBsAg proteins was investigated. 
The presence of such binding site might explain the role of the two HMg's during HSV 
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The presence of such binding site might explain the role of the two HSAg's during HSV 
particle formation. Transfection studies with HSV cDNA and HBV DNA constructs 
demonstrated that LSAg is required for HSV formation, presence of small HBsAg is 
sufficient and that SSAg is only packaged when LSAg is present. In a solid phase 
bindingstudy LSAg was able to bind to all three HBsAg proteins via small HBsAg sequences. 
This must be the reason that LSAg can form HSV-like particles, in vitro in the presence of 
only small HBsAg. SSAg was not able to interact with small HBsAg sequences. The coat of 
HSV exists predominantly of small HBsAg. Based on these facts it is obvious that L<5Ag and 
not SSAg plays an essential role in HSV particle formation. However on SSAg a specific 
binding site for the PreS2 sequences of middle HBsAg was identified. Whether the 
interaction between SSAg and middle HBsAg plays a role in the Ηδν life-cycle remains to 
be resolved. 
The coat of HSV exists of HBsAg, although in another composition as in the HBV coat. It 
is therefore likely that HSV will be able to interact with the HBsAg binding protein 
endonexin II. In chapter 6 HSV particles were enriched from chimpanzee serum and 
incubated with recombinant endonexin II. The HSV particles were specifically immuno-
precipitated after incubation with anti-endonexin II. In a solid phase binding assay with 
recombinant proteins the binding of LSAg via HBsAg to endonexin II was confirmed. 
Moreover, the binding of native HSV particles to human hepatocytes was inhibited by 
incubation with anti-endonexin II and anti-anti-endonexin II (anti-HBsAg) antibodies. These 
results implicate that HSV via its coat of HBsAg can interact with human liver endonexin II. 
HBV by delivering HBsAg for the Ηδν coat indirectly enables HSV to utelize the HBV 
receptor. 
In literature a lot of discussion exists about the localization of the hepatocyte binding site on 
HBsAg. A role for the PreSl region of large HBsAg has often been mentioned, but until now 
no specific PreSl binding protein has been identified. Because the coat of HSV contains less 
than 1% large HBsAg, it is expected that this virus makes use of another receptor molecule 
to infect human hepatocytes. The results described in chapter 6 demonstrate that HSV is able 
to interact with human liver endonexin II and indicate that HSV might use the same receptor 
molecule to infect human hepatocytes as HBV. 
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Endonexin II is the only identified specific HBsAg binding liver protein so far. Although the 
results described in chapter 2 and 3 of this thesis contribute to the hypothesis that endonexin 
II has a function as HBV receptor, further experiments to establish this role of endonexin II 
are necessary. When non-permissive cell lines transfected with endonexin II cDNA should 
become susceptible for an infection with HBV or monoclonal antibodies directed to the 
HBsAg binding epitope of endonexin II are able to block infection with HBV in permissive 
cells, the evidence is complete. The anti-endonexin II monoclonal antibody might then 
become a valuable tool in treatment of chronic HBsAg carriers. Elimination of HBV will 
naturally result in removal of HôV. 
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Samenvatting en conclusies 
Een groot deel van de klinische hepatitis wordt veroorzaakt door een infectie met een van 
de vijf tot nu bekende hepatitis virussen (HAV-HEV). Twee hiervan, het hepatitis В virus 
(HBV) en het hepatitis delta virus (H5V) zijn sterk aan elkaar gerelateerd. De mantel van 
deze virussen zijn beiden opgebouwd uit de drie hepatitis В oppervlakte eiwitten 
(HBsAg): small-, middle- en large HBsAg. De verhouding waarin deze eiwitten in de 
mantel van de virussen voorkomen is echter verschillend. H5V is afhankelijk van de aan­
wezigheid van het HBV, voor de voltooiing van zijn eigen infectiecyclus. 
Het HBV heeft een sterke gastheer- en weefselspecificiteit. Het infecteert alleen de mens 
en sommige niet-humane primaten, zoals de chimpansee en vermenigvuldigt zichzelf 
voornamelijk in de lever van deze organismen. Een mogelijke verklaring voor dit 
fenomeen zou de aanwezigheid van specifieke receptor voor het virus op de levercellen 
van deze species kunnen zijn. Endonexine II, geïsoleerd uit humaan leverweefsel, werd 
als HBsAg bindend eiwit geïdentificeerd. Het onderzoek dat in dit proefschrift wordt 
beschreven, richt zich op het HBsAg en het HBsAg bindend eiwit endonexine II. 
Na immunisatie van konijnen met humaan lever endonexine II, werden niet alleen anti-
humaan endonexine II antilichamen, maar ook anti-idiotypische antilichamen gevormd. 
Deze anti-anti-endonexine II antilichamen reageren met HBsAg. Dit geeft aan dat een 
receptor-ligand relatie tussen endonexine II en HBsAg moet bestaan. In hoofdstuk 2 wordt 
HBsAg, geconjugeerd aan 10 nm collodiol goud, gebruikt om de binding en internalisatie 
van HBsAg door humane hepatocyten met behulp van elektronenmicroscopie te bestude-
ren. Hiertoe werden hepatocyten bij 4°C met HBsAg-goud geincubeerd. Verwarmen van 
de cellen tot 37°C resulteerde in de directe invaginatie van de coated pit regio waaraan het 
HBsAg was gebonden. Incubatie van de hepatocyten met anti-endonexine II antilichamen 
of het HBsAg met anti-idiotypisch (anti-HBsAg) antilichamen resulteerde beide in de 
specifieke inhibitie van de binding van het HBsAg-goud aan de humane hepatocyten. 
Deze resultaten geven duidelijk aan dat het humane endonexine II betrokken is bij de 
binding en internalisatie van HBsAg, waarschijnlijk als HBV receptor. 
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Zoals eerder al is vermeld, vertoont het HBV een sterke species- en weefselspecificiteit. 
In hoofdstuk 3 wordt de relatie tussen de aanwezigheid van het HBsAg bindend eiwit 
endonexine II en de species-specificiteit van het HBV aangetoond. Op immunoblot werd 
HBsAg bindend endonexine II alleen gedetecteerd in leverweefsel van species, die 
gevoelig zijn voor een HBV infectie. De plasma membraanfracties van deze weefsels 
waren bovendien in staat specifiek HBsAg te binden. Deze resultaten geven aan dat er een 
correlatie bestaat tussen de aanwezigheid van het HBsAg-bindend eiwit endonexine II en 
de species-specificiteit van het HBV. Het voorkomen van endonexine II bleek echter niet 
beperkt tot de lever. Ook in andere humane weefsels kon het eiwit worden aangetoond. 
De leverspecificiteit van HBV is dus niet gecorreleerd aan de weefselspecifieke expressie 
van het endonexine II. De extra-hepatische aanwezigheid van endonexine II kan echter 
wel de detectie van HBsAg, HBV DNA en HBV DNA transcripten in niet-hepatisch 
weefsel verklaren. Hoewel HBV in sommige extra-hepatische weefsels kan repliceren, is 
de lever de belangrijkste plaats voor virale replicatie. De beste verklaring hiervoor moet 
dan ook gezocht worden in de leverspecifieke factoren die de replicatie van het HBV 
DNA reguleren. 
In hoofdstuk 4 wordt, met behulp van oligonucleotides gesynthetiseerd volgens cDNA 
sequenties van endonexine II uit placenta, endonexine II cDNA uit een lever cDNA bank 
geïsoleerd. Het endonexine II cDNA wordt in een baculovirus expressie systeem 
gekloneerd. Het resulterende recombinant endonexine II heeft hetzelfde moleculegewicht, 
isoelectrisch punt en HBsAg bindende eigenschappen als het natieve eiwit. Het is 
bovendien heel eenvoudig te zuiveren volgens methodes, die al eerder voor natief 
endonexine II uit placenta beschreven werden. Hoewel er verschillende functies voor het 
endonexine II geopperd zijn is de exacte biologische functie van het eiwit nog niet 
bekend. Aangezien het recombinant eiwit dezelfde eigenschappen als het natieve eiwit 
bezit, zou het in de toekomst een belangrijke rol kunnen spelen, niet alleen in HBV 
onderzoek, maar ook om de biologische functie van het endonexine II te bepalen. Het 
recombinant eiwit is gebruikt in de experimenten beschreven in hoofdstuk 6. 
125 
CHAPTER 7 
Het Ηδν bestaat uit een core van hepatitis delta antigen (HôAg) en het Ш RNA 
molecule omgeven door een mantel van HBsAg. Deze viruspartikels moeten op een of 
andere manier tijdens de HSV levenscyclus worden gevormd. In hoofdstuk 5 wordt 
bestudeerd of op het small H5Ag (SôAg) en large HÔAg (LóAg) eventuele reactieve 
bindingsplaatsen aanwezig zijn voor het HBsAg. Het bestaan van deze bindingsplaatsen, 
zou mogelijk een verklaring kunnen bieden voor het gedrag van beide eiwitten bij de 
formatie van HSV partikels. Transfectie studies met HÔV cDNA en HBV DNA construc-
ten hebben duidelijk gemaakt dat aanwezigheid van L5Ag nodig is voor partikelformatie, 
dat de aanwezigheid van het small HBsAg voldoende is en dat het SöAg alleen in 
partikels kan worden ingepakt als het LÓAg aanwezig is. In een bindingsstudie bleek 
L5Ag via small HBsAg sequenties alle drie de vormen van HBsAg te binden. Dit is 
waarschijnlijk de reden, dat het LSAg in vitro in aanwezigheid van enkel het small 
HBsAg, al in staat is HôV-achtige partikels te vormen. 
Het SôAg bleek geen interactie met de small HBsAg sequenties aan te gaan. Aangezien de 
mantel van het HÔV voor 95% uit small HBsAg bestaat mag duidelijk zijn, waarom het 
LMg een essentiële rol speelt bij de vorming van het HôV. Het SôAg bleek echter wel 
een reactieve bindingsplaats voor de PreS2 sequenties van het middle HBsAg te bezitten. 
Of de interactie tussen deze eiwitten een rol speelt in de levenscyclus van het HôV is nog 
onduidelijk. 
Hoewel de mantel van het HSV net als bij het HBV is samengesteld uit HBsAg, is de 
verhouding waarin small-, middle- en large HBsAg voorkomen verschillend. In het serum 
van HBV geïnfecteerde patiënten komen naast viruspartikels ook niet-infectieuze 22 nm 
HBsAg partikels en filamenten voor. De opbouw van deze HBsAg deeltjes is anders dan 
van de HBV mantel. De samenstelling van de mantel van het HÔV vertoont grote 
overeenkomsten met de opbouw van de non-infectieuze partikels. Het ligt voor de hand, 
dat het HÔV via zijn oppervlakte eiwitten ook in staat zal zijn een interactie met het 
HBsAg-bindend eiwit endonexine II aan te gaan. In hoofdstuk 6 worden H5V partikels 
geïsoleerd uit chimpansee serum, geïncubeerd met endonexine II. Vervolgens werd tijdens 
een immuunprecipitatie met anti-endonexine II specifiek H5V geprecipiteerd. Met behulp 
van bindingsstudies met recombinant eiwitten werd nog eens bevestigd, dat het L6Ag via 
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HBsAg in staat is endonexine II te binden. Bovendien kon de binding van natieve H5V 
partikels aan humane hepatocyten met antilichamen tegen endonexine II en anti-anti-
endonexine II (anti-HBsAg) worden geblokkeerd. Dit impliceert dat het HÔV via zijn 
mantel mogelijkerwijs van dezelfde receptor gebruik kan maken als het HBV. 
In de literatuur bestaat veel discussie over de exacte lokalisatie van de bindingssplaats 
voor de levercel op het HBsAg. Een rol voor de PreSl regio van het large HBsAg is vaak 
genoemd, maar tot nu toe is er nog geen specifiek PreSl bindend eiwit geïdentificeerd. 
Aangezien de mantel van het Ш voor minder dan 1% uit large HBsAg bestaat, gaat 
men ervan uit, dat dit virus een ander receptor molecule gebruikt als het HBV om de 
levercel te infecteren. De resultaten beschreven in hoofdstuk 6 demonstreren dat HSV in 
staat is om met het humaan endonexine II aan te gaan en geven aan, dat het Ш 
mogelijk van dezelfde receptor molecule gebruik maakt als het HBV, om de levercel te 
infecteren . 
Humaan endonexine II is het enige specifiek HBsAg bindend eiwit dat momenteel bekend 
is. Hoewel de resultaten beschreven in hoofdstuk 2 en 3 van dit proefschrift een bijdrage 
leveren in de bewijsvoering, dat het endonexine II inderdaad als HBV receptor fungeert, 
zal toch meer onderzoek nodig zijn om deze hypothese te bevestigen. 
Wanneer niet-permissieve cel lijnen, getransfecteerd met endonexine II cDNA, gevoelig 
worden voor een HBV infectie of als monoklonale antilichamen, gericht tegen het HBsAg 
bindingsepitoop van endonexine II, in vitro de infectie van HBV in gekweekte humane 
hepatocyten kunnen blokkeren, is het bewijs voor de theorie compleet. Deze anti-
endonexine II monoklonale antilichamen zullen in de toekomst mogelijk een belangrijke 
rol kunnen spelen voor de genezing van chronische HBsAg dragers, door bij deze 
patiënten de infectie cyclus te doorbreken. Het verwijderen van het HBV, zal automatisch 
leiden tot de eliminatie van het HôV. 
127 

LIST OF ABBREVIATIONS 
AcNPV 
bp 
BSA 
CBB 
cDNA 
cpm 
DAB 
DMSO 
DNA 
DR1/DR2 
DTT 
EDTA 
ELISA 
EGTA 
ER 
FCS 
g 
GST-T 
HAV 
HBcAg 
HBeAg 
HBsAg 
HBV 
HBxAg 
HCC 
HCV 
HÄV 
HiAg 
HEV 
HNF-1 
IEF 
Kb 
kD 
LiAg 
мне 
MOI 
Mw 
mRNA 
ORF 
PAGE 
PBS 
PBST 
PMSF 
RT 
SDS 
Autographs cahfornica nuclear 
polyhidrosis virus 
base pairs 
bovine serum albumin 
coomassie bnlliant blue 
copy DNA 
counts per minute 
3,3-diaminebenzidine 
dimethylsulfoxide 
deoxynbonucleic acid 
direct repeat 1 and 2 
dithiotreithol 
elhylenedianunetetraacetic acid 
enzyme linked immunosorbant 
assay 
ethylenebis(oxyethelenenitnlo) 
tetraacetic acid 
endoplasmatic reticulum 
foetal calf serum 
gravity force 
gluthathion S transferase τ 
hepatitis A virus 
hepatitis В core antigen 
hepatitis В early antigen 
hepatitis В surface antigen 
hepatitis В virus 
hepatitis Β χ antigen 
hepatocellular carcinoma 
hepatitis С virus 
hepatitis delta virus 
hepatitis delta antigen 
hepatitis E virus 
hepato-nuclear factor I 
iso-electro focussing 
kilobases 
kilodalton 
large hepatitis delta antigen 
major histocompatibility 
complex 
•nullification of infection 
molecular weight 
messenger RNA 
open-reading frame 
Polyacrylamide gel electroforese 
phosphate buffered saline 
PBS/tween 
phenylmethylsulfonylfluonde 
room temperature 
sodiumdodecylsulfate 
Sf9 Spodoptera Frugiperda 
SÓAg small hepatitis delta antigen 
SRP signal recognition protein 
SSC sodium chlonde/citrate 
SV-40 Simian virus 40 
WEM William's essential medium 
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SLOTWOORD 
Op de titelpagina van dit proefschrift staat slechts een auteur vermeld. Natuurlijk zijn veel 
meer personen bij de totstandkoming ervan betrokken geweest. Uit angst onbewust 
iemand te vergeten, wil ik in algemene zin mijn erkentelijkheid uitspreken aan iedereen 
die er toe heeft bijgedragen, dat deze "joint venture" tot een goed einde is gekomen. 
0** 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd op 16 september 1963 te Geldrop geboren. Zij 
bezocht het Dominicus College te Nijmegen, alwaar in 1982 het atheneum-B diploma 
werd behaald. September van dat jaar werd met de studie Biologie aangevangen aan de 
Katholieke Universiteit Nijmegen. Het doctoraal met de afstudeervakken Dierfysiologie, 
Hematologie en Didactiek werd op 24 november 1987 behaald. Vanaf 1 maart 1988 tot 1 
maart 1992 had zij een aanstelling als onderzoeker in opleiding op de de afdeling Gastro-
enterologie van het Academisch Ziekenhuis Nijmegen. Daarna is zij als vrijwilligster op 
deze afdeling werkzaam geweest. Het onderzoek dat in het kader van deze aanstellingen is 
verricht, resulteerde in het verschijnen van dit proefschrift. Momenteel is zij junior 
onderzoeker op genoemde afdeling. 
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STELLINGEN 
1. De species specificiteit van het hepatitis В virus is gecorreleerd aan de soort specifieke 
eipressie van het HBsAg bindend eiwit endónenme II. (Dit proefschrift). 
2. Endonexine II is betrokken bij de specifieke binding en internalisatie van het HBsAg door 
humane hepatocyten en is dus een goede kandidaat als hepatitis В virus receptor. (Dit 
proefschrift). 
3. De relatie tussen het hepatitis В ел hepatitis delta virus is gebaseerd op het gemeenschappe­
lijk gebruik van hepatitis В oppervlakte eiwitten voor interactie met de mogelijke hepatitis В 
virus receptor endonexine II. (Dit proefschrift). 
4. Het feit dat annexine I, net als endonexine II, geen transmembraan sequentie bevat, maar 
toch kan worden uitgescheiden, wijst op het bestaan van een eventueel nieuwe secretie 
pathway. (Raynal & Pollard, 1994, BBA 1197, p. 63-93). 
5. Aangezien endonexine II een even potent antistollingsfactor is als héparine, maar geen 
verlenging van de protrombinetijd geeft, is het mogelijkerwijs een bruikbaar therapeutisch 
middel voor veneuze thrombose. 
(VanrynmcKemu et al., 1993, Thromb. Heamast. 69, p. 227-230) 
(Van Heerde et al., 1994, Arteriös, and Thromb. 14, 824-830). 
6. Het verkleinen van de groente-, fruit- en tuinafval (GFT) kringloop door het aanleggen van 
composthopen in particuliere tuinen, biedt naast economisch gewin, tevens een oplossing 
voor de afzerproblematiek van gecomposteerd GFT. 
7. Wanneer de benaming van de uitkering van werklozen, die vrijwilligerswerk verrichten, 
wordt gesubstitueerd door loon, zal het werkloosheidscijfer aanzienlijk dalen en het 
maatschappelijk aanzien van de betrokken personen stijgen. 
8. De economie stelt zelfs grenzen aan de milieu-eisen. 
9. De werktijden van een groot aantal individuen uit een- en tweepersoonshuishoudens, zijn 
door de verruiming van de winkelsluitingswet verlengd. 
10. Het verschil in vrouwelijke sporters van het platteland en uit stedelijk gebied komt onder 
andere tot uitdrukking in de periode van allieve sportbeoefening vóór de procreatiezorg. 
(R. Jeurissen, NBB). 
11. Tijdens de vakantieperiode in de maanden juli en augustus besef je pas hoe dichtbevolkt 
Nederland is. 
12. Auto-alarminstallaties veroorzaken vooral veel geluidshinder. 
Stellingen behorende bij het proefschrift 'Role for human endonexin II in hepatitis В and hepatitis-
delta virus infection", Wieke de Bruin, augustus 1994. 



